Grant Life Sciences, Patenterteilung!!! Bioaktie mit Megapotenzial!!! - 500 Beiträge pro Seite (Seite 3)

[estewe]

urlaub von wo

[estewe]

na werden wir die 25 als sk halten ?

[estewe]

so wie es aussieht ist er auch dort, bloß macht er alles andere als schnorcheln.


By: arcoo1
20 Dec 2005, 11:55 AM EST
Msg. 1464 of 1467
Jump to msg. #
greet all Germany of malle (:

(Voluntary Disclosure: LT Rating- Strong Buy)

[flussaufwerz]

sieht nach 0,04 aus

[estewe]

nix dagegen dann wär mein glif depot grün und das war es schon ne weile nicht mehr

[estewe]

rt 0,027 ask 0,027 bid 0,0255

[flussaufwerz]

ab 0,027 zieht es bei manchen
furchtbar am hintern da läd dan der pirat ab
das was ihn der spass bisher gekostet hat

[estewe]

[posting]19.355.980 von flussaufwerz am 20.12.05 20:03:44[/posting] arca ?

[estewe]

alles andere wäre vermutlich ekelig

aber nun gut, das war´s für mich und heute go glif
bis denn

[flussaufwerz]

ja der
http://www.archipelago.com/video/birds_mkt_vol.mpg

[moneyonstreet]

kommt noch dritter schwung auf 0,04

rt 0,031

[medom]

das haben wir uns verdient, nach der durststrecke

[flussaufwerz]

sieht so aus als ob ich mich
schon bald von euch verabschieden darf
war mir ein kurzes vergnügen
werde aber glif im auge behalten und
mal sicher wieder vorbeischauen
schöne festtage an alle

[medom]

und tschüüüüüüüüüüüüüüüs

[moneyonstreet]

my posting from yesterday


#995 von moneyonstreet 19.12.05 23:43:03 Beitrag Nr.: 19.344.891
Dieses Posting: versenden | melden | drucken | Antwort schreiben

what a game

- wall at 0,015 usd on the bid side
- next level 0,01 usd
- no pr
- discussions boards seems to be dead

yeeeeeaaaaaah, thats otc.... thats the job of five-star-manipulators

[moneyonstreet]

und heute.... buuuuuuuuummmmmmmmmmmm

kurzes buuummm oder langes buuummmmm

i say looooong buuummmmmmmmm, flussaufwärts kommt wieder

[moneyonstreet]

schüttel-raus-technik-level-one-and-come-back was today

posted December 20, 2005 12:12
--------------------------------------------------------------------------------
I wouldn`t be surprised at all to see another bounce this afternoon, but I think when we get the monthly PR you will see a lot of increased interest in this stock. And,no I don`t know when we will get another PR, but it is overdue.
========================================================

posted December 20, 2005 14:40
--------------------------------------------------------------------------------
I am very impressed by the upward
potential of GLIF. This is the worst
time of the year to make a run, and it
jumped up 40% twice in a day, without
a pr. This is only part of the MMs`
game plan -- to shake out year end
tax-sellers. The MMs are not selling
yet. It`s a great gamble to wait for
the PR. Now, you know even when to get
out is a gamble.

============================================================
posted December 20, 2005 15:10
--------------------------------------------------------------------------------
Hi, Mgordy. I believe every trade is a gamble --
like to get in or not to get in, at what level to
get in. Now, to get out or not to get out, and
at what pps to get out, every step is a gamble. Now
I gamble on the assumption that the MMs have
enough cheap shares, and we are not going to
see anything under 0.02 until the whole cycle
is over. This is my gamble. Every body must
play their own game . I hate to see people to
complain that they get out too early, or too
late. Play a good game, and have fun.

==========================================================

posted December 20, 2005 16:23
--------------------------------------------------------------------------------
glif will go to .45 get in!!!!!!!!!!
well organized group is going to run this!!!

--------------------
Leadership is lifting a person`s vision to higher sights, the raising of a person`s performance to a higher standard, the building of a personality beyond its normal limitations."

--------------------------------------------------------------------------------

[moneyonstreet]

schaut... schaut ihr bergsteiger, nach kräftiger rutschbahn schöne zwei gipfel bestiegen aber auch wieder in das tal herab gestiegen ;aber die täler sind nicht mehr so tief . die frage ist, wie hoch ist der nächste gipfel, vielleicht ein zehntausender mit gaaaaaaanz laaaaaaaaaangem aufstieg . we will see

[moneyonstreet]

@ arcoo

2006 will be glif-year ... mark this post ... i say market-cap min. 50 mill. usd is no problem (no guarantee)... perhaps over 100 mill. usd with lucky punch... again: whats o/s by the time. GLIF is coming

0,1
0,5
1,0 arcoo long

[moneyonstreet]

market-cap today so knapp 2,8 mill. usd

noch viel luft.. oder

perhaps tomorrow gewinnmitmahnen.. von mir nicht .. glif long

[moneyonstreet]

[posting]19.357.127 von flussaufwerz am 20.12.05 21:33:57[/posting]greets and thanks to you... happy x-mas and the best for 2006. if you watch glif, you come back very soon... 2006 is glif-year .

[moneyonstreet]

very nice play.. here the bullish side

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

By: gpa15
20 Dec 2005, 05:11 PM EST
Msg. 1519 of 1520
(This msg. is a reply to 1518 by bemilio007.)
Jump to msg. #
bem- It`s actually not very high if you look at the chart. Besides most people have bought it alot higher.

1) This company is serious and have some good management and scientist trying to do develop a business. Not like other OTC stcoks which are fake.

2) at 200M shares its valued at $6M (at 0.03 pps) whcih is peanuts

3) The stcok has come down from a $1 all the way to 0.015 in the last year. However it has got a lot of visibility in the last few months, i.e. more stck holders now and more waiting in the sideline to jump in.

4) It should have been going up except for the financing which made the investors sell taking the price down from 0.06 to 0.015 in the last few weeks.

5) It seems like no investor selling happening now. If thats the case this will continue to move up as retail investors would value it much higher.

6) The last bounce was to 0.15 and was stable at 0.06 until the investors started selling. I expect it to back to that level if no investors selling.

7) If you look at the chart and the 50 day, 200 day etc, it is likely to go to 0.17 (IMO)

8) If investors are still left wiuth shares and going to sell, all bets are off and we are back to the gutters.

9) The company will ask for more shares authorization in January and we`ll again hit turbulkent times.

10) If some exceptional good news comes out, I expect a trend reversal and continued increased in value of the company and the pps.

This IMO ofcourse.

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

[moneyonstreet]

now the bashers-side... make your own DD... i`ve just done

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

By: volumetrader55
20 Dec 2005, 06:00 PM EST
Msg. 1520 of 1520
Jump to msg. #
[[[[[[[dont get to exicted]]]]]]]]]

This move was just a MM covering of shares they have profited shorting. GLIF will be back under .01 in January . There is a lot more shares to be dumped at the bid by the Financiers of the Death Spiral financing IMHO. TEmporary book closing covering going on to lock in profits for this year.

[moneyonstreet]

what a game

[moneyonstreet]

gehört auch zum game

http://www.americanbulls.com/StockPage.asp?CompanyTicker=GLI…

[moneyonstreet]

@ medom

for you...sieht morgen noch besser aus

[moneyonstreet]

no comment.. that`s a major trend-setter with great technical analysis

http://quotes.barchart.com/texadv.asp?sym=glif

[moneyonstreet]

dollar is dollar

[DeluxeTrader]

GEIL !!!

Ich wusste, das hier was kommt!

Hammer!

Seid ihr noch alle drin ??

Gabs ne Meldung oder was ist passiert?!

[stupidgame]

[posting]19.362.078 von DeluxeTrader am 21.12.05 10:43:58[/posting]Hier gibt es ja einen Thread. Ja, mir ist die gestern auch aufgefallen. High-Volume-Breakout. Ganz klar. Nur, ich hätte in FF die 0,03€ nicht abgeräumt. Die wären mir zu teuer. Gestern hat sich ein Aufwärtstrend gebildet. Die Unterkante läuft zur Eröffnung USA bei ca. 0,024-0,025$. In der Nähe dieser Trendlinie würde ich heute veruchen was zu bekommen. SL - ganz klar - Bruch derselben.
MfG.

[Exploser]

heute knallt`s in den USA...!!!!!

[moneyonstreet]

GRANT LIFE SCIENCES INC Quick Quote: GLIF 0.03 (Even)




otcstockexchange.com: Mid-Day Stock Alert -- OTCStockExchange.com DCBI, CYOS, GLIF , GBVS
12/20/05

Rochester, NY, Dec 20, 2005 (M2 PRESSWIRE via COMTEX) --
OTCStockExchange.com`s "Mid-Day Stock Watch Alert" this afternoon are DC Brands International, Inc. (Pink Sheets: DCBI), CYOP Systems International Inc. (OTCBB: CYOS), Grant Life Sciences Inc. (OTCBB: GLIF), Global Beverage Solutions Inc. (OTCBB: GBVS).

Sign-up for our FREE Stock Alerts at http://www.otcstockexchange.com !

DC Brands International, Inc. (Pink Sheets: DCBI - http://finance.yahoo.com/q?s=DCBI.PK ) DC Brands International, Inc. markets its Dickens Energy Cider through a growing network of distributors nationwide. The company announced that the recent trip to Florida by the company`s President Dick Pearce and their V.P. of Sales Buck Adams was extremely successful. Mr. Adams said: "We met with major beer distributors in Orlando, Palm Beach and Miami. All three meetings went extremely well and all three distributors are now in the contract stage. We will not release names until contracts are signed. However, I will tell you that we expect all three to be finalized mid-January. The exciting thing for us is the fact that these new relationships will give our brand exposure to more than 15,000 new accounts and should generate a minimum of $100,000 a month in revenue for the company by early spring on our original energy drink products alone, plus additional revenue from our new bag-in-the-box and alcoholic products we are releasing." (See previous article "DC Brands Announces new Bag in the box and Alcoholic product.") Additionally, the company`s President and CEO was interviewed a few weeks ago by the Wall Street Reporter, the approximate 15 minute audio file is available at www.wallstreetreporter.com and provides a very good idea of the company`s history, position and future goals. Once at the home page, look to the right-hand side, scroll down to the OTC section and look for the file marked Dick Pearce CEO DC Brands International.

For more information on the company, visit their Web site at www.DickensEnergyCider.com.

CYOP Systems International Inc. (OTCBB: CYOS - http://finance.yahoo.com/q?s=CYOS.OB ) CYOP Systems International Inc., a provider of online gaming software and operator of games portals, is pleased to announce an executed agreement with FutureBet Systems Inc., to purchase 40 online casino games and SportsBook software and platform for $1,200,000.00 on terms.

Some of the casino features are an icon driven menu system, an intuitive Quick Menu that allows the user to jump from game in a single click, higher graphics resolution and many other industry revolutionizing features. The software is offered in an Instant Play/No download Flash version and a stand alone Windows application that is the smallest download online.

The games have been translated in the following 9 languages: Japanese, Spanish, French, Dutch, German, Italian, Korean, Russian, and English.

Casino games that will be in the Company`s tournament software include:

Blackjack American Roulette European Roulette Mini-Baccarat Deuces Wild Video Poker Jacks or Better Video Poker Joker Wild Video Poker Classic Slots Cash Bash Slots Caribbean Poker Ride On Poker Pai Gow Poker Craps Casino War Red Dog Three Card Poker

The Internet Sports Wagering Software covers North American and International sports and events. The software purchase also includes a full suite of reporting tools designed especially for licensing to third parties.

The Company now has a suite of games that rivals the depth of proprietary software for companies such as SportingBet PLC, Chartwell Technology Inc., CryptoLogic Inc. and WorldGaming PLC.

With its cross platform of brands including flash casino games, downloadable casino games, sports betting software and skill games, CYOP now has the opportunity to build a truly global presence.

The new version of games and the platform will be linked into CYOP`s licensed CrediPlay tournament system allowing for multiplayer use as well as single-player. The Company also has agreements in place with payment processors to integrate multiple online ecommerce options.

The online gambling industry is the fastest growing industry on the Internet. Global revenues from online gambling will reach USD $15 billion in 2006, up from USD $10 billion in 2005 and USD $7.0 billion last year. According to Christiansen Capital Advisors, LLC for the five-year period from 2005 to 2009, it is estimated that revenues generated by the global online gaming market will increase to approximately $22.7 billion, representing a compound annual growth rate of approximately 22 per cent.

Mitch White, CEO of CYOP, commented, "We looked at many gaming systems and decided this suite of games, platform and sports software represented the finest interactive compilation available anywhere. These games are the highest of quality and designed with the customer in mind. They combine state of the art graphics with Las Vegas style odds. By purchasing tested software, we are able to focus on operations, get to the market sooner, and at the same time continue our development of games."

Grant Life Sciences Inc. (OTCBB: GLIF - http://finance.yahoo.com/q?s=GLIF.OB ) Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons.

Global Beverage Solutions Inc. (OTCBB: GBVS - http://finance.yahoo.com/q?s=GBVS.OB ) Global Beverage Solutions Inc. announced Titanium Design Studio Inc. (TDS) has filed a registration statement with the State of Nevada to raise up to $160,000 through the sale of 8,000,000 shares of its common stock. This registration of the TDS shares is the first step toward TDS becoming a stand-alone publicly traded company.

"We are pleased with TDS` decision to become a publicly traded company. This decision will enable Global to completely shift its emphasis to the beverage industry by giving Global`s TDS shares a readily ascertainable market value, which in turn could lead to the TDS shares being used either as a dividend to Global`s shareholders or being sold through the market place," stated Rick Clark, President of GBVS.

About OTCStockExchange.com

OTCStockExchange.com (OTCS) is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. OTCS is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. OTCS`s goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. OTCS provides all investors with the latest news, press releases, investment opinions, and research reports for all the companies highlighted on the site. OTCS offers a free financial newsletter. To subscribe or get more information, visit our home page located at http://www.otcstockexchange.com.

We offer many investor relations programs to public companies. To feature a company on our web site or in our daily Newsletter or Mid-Day Stock Alert, please contact Chris Wheeler at 585-330-8514 , or via email at [e-mail].

OTCStockExchange.com (OTCS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by OTCS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTCS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.otcstockexchange.com or mentioned herein. OTCS has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion.

OTCS has been compensated by third party shareholders or with cash from the company on behalf of DCBI. OTCS has been compensated 500,000 shares on behalf of DCBI for dissemination of this opinion and other professional services.

OTCS`s affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. OTCS will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies` annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and OTCS undertakes no obligation to update such statements.

CONTACT: Chris Wheeler Tel: [phone] e-mail: [e-mail] WWW: http://www.otcstockexchange.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2005 M2 COMMUNICATIONS LTD

© 2005 Stockgroup Media Inc. | Disclaimer

[moneyonstreet]

GRANT LIFE SCIENCES INC Quick Quote: GLIF 0.03 (Even)




OTCPicks.com: Daily Market Movers Digest Midday Stock Alerts, Tuesday, December 20th, CLSN, PTII, CYOS, SGIHF, GLIF , HYBT
12/20/05

Dec 20, 2005 (M2 PRESSWIRE via COMTEX) --
Today our stock watch alerts today include Featured Profiles for Chelsea Collection (OTC: CLSN), Patch International, Inc. (OTCBB: PTII) and stock alerts for CYOP Systems International Inc. (OTCBB:CYOS), Sungold International Holdings Corporation (OTCBB: SGIHF), Grant Life Sciences Inc. (OTCBB: GLIF), Hybrid Technologies Inc. (OTCBB: HYBT) FEATURED STOCK PROFILE

GRANT LIFE SCIENCES, INC. (OTCBB: GLIF) "Up 46.34% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/GLIF.php

Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious, or economic reasons. Further information is available at: www.grantlifesciences.com.

[moneyonstreet]

GRANT LIFE SCIENCES INC Quick Quote: GLIF 0.03 (Even)




Stockguru.com: Guru Alerts for Wednesday, December 21, 2005 CEMI, GLIF , USTT, NPHC. 12/21/05

Dallas, Texas, Dec 21, 2005 (M2 PRESSWIRE via COMTEX) --
Stock Guru Alerts for Wednesday include Chembio Diagnostics Inc. (OTCBB:CEMI), Grant Life Sciences, Inc. (OTCBB: GLIF), USA Technologies, Inc. (OTCBB: USTT), and Nutra Pharma Corporation (OTCBB: NPHC)

To feature your publicly traded company in our alerts, email [e-mail] or call [phone] and we will gladly send more information on featuring your company with StockGuru.com.

Chembio Diagnostics, Inc. (OTCBB:CEMI) closed down at .89%, trading 100 shares on Tuesday.

To View the StockGuru.com Profile of Chembio Diagnostics, Inc., please visit: http://www.stockguru.com/profiles/cemi/ Chembio Diagnostics, Inc. (OTCBB: CEMI) is a US-based producer of rapid HIV and other rapid tests for infectious diseases using innovative, socially responsible marketing approaches to help meet testing challenges in Africa, South America, and Asia. Chembio`s goal is to ensure sustainable supplies of simple, accurate, cost-effective rapid tests to all those who need them.

Formed in 1985 as a research and development company, Chembio began manufacturing rapid HIV tests in 2001 and is currently developing a rapid test for tuberculosis that will leverage existing marketing efforts.

Chembio`s HIV tests are registered for sale in more than forty countries. The HIV 1/2 Stat-Pak and HIV 1/2 Stat-Pak Dipstick tests are currently on the World Health Organization 2005 Bulk Procurement Scheme and are also, together with Sure Check HIV on the USAID Blanket Waiver List, allowing them to be procured with USAID and other donor government funds.

Grant Life Sciences, Inc. (OTCBB: GLIF) traded as much as 82.93% over open on Tuesday.

Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.

USA Technologies, Inc. (OTCBB: USTT) closed down at 8.26%, trading 11,272,610 shares on Tuesday.

USA Technologies is a leader in the networking of wireless non-cash transactions, associated financial/network services and energy management. USA Technologies provides networked credit card and other non-cash systems in the vending, commercial laundry, hospitality and digital imaging industries. USA Technologies is an IBM Business Partner. The Company has marketing agreements with Cingular Wireless, Honeywell, MEI, and ZiLOG Corporation. For further information on USA Technologies, please visit www.usatech.com

Nutra Pharma Corporation (OTCBB: NPHC) remained unchanged at .23 per share, trading 518,555 shares on Tuesday.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company`s holding, ReceptoPharm, Inc, is developing technologies for the development of drugs for HIV and Multiple Sclerosis ("MS"). The Company`s other holding Infectech, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena. http://www.nutrapharma.com About StockGuru.com:

StockGuru.com features daily alerts going out three times daily to members. To join our email alert list, please visit: http://www.stockguru.com/stocks.htm To feature your publicly traded company in our alerts, or to discuss our complete services, please contact: John Pentony at [phone]. Our services include our Morning, Midday and After The Bell News Releases. Additionally we Profile publicly traded companies on our web site, we do interviews with CEO`s or other key executives on our web site, and we have our financial writers cover our companies.

Those interested may also email: [e-mail] and we will gladly send more information on featuring your company with StockGuru.com.

Stockguru.com ("SG") provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies` annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements.

Disclosure: Chembio Diagnostics, Inc. (OTCBB:CEMI) Pentony Enterprises LLC was compensated $9000 cash for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

CONTACT: John Pentony, Publisher Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2005 M2 COMMUNICATIONS LTD

© 2005 Stockgroup Media Inc. | Disclaimer



GLIF Releases SHfn

Stockguru.com: Guru Alerts for Wednesday, December 21, 2005 CEMI, GLIF, USTT, NPHC.

otcstockexchange.com: Mid-Day Stock Alert -- OTCStockExchange.com DCBI, CYOS, GLIF, GBVS

OTCPicks.com: Daily Market Movers Digest Midday Stock Alerts, Tuesday, December 20th, CLSN, PTII, CYOS, SGIHF, GLIF, HYBT

TwinTrader.com: Twin Trader Alerts for Friday, December 16, 2005 CHID, SMVD, EDNE, GLIF.

Stockguru.com: Guru Alerts for Monday, December 12, 2005 OGHC, NEOM, TPLM, GLIF.


SH @ the Bell: U.S. Traders Spin Their Tires

Securities Sleuth: SeraCare Life Sciences (NASDAQ: SRLS)

SH @ the Bell: Tech Wrecks Wall Street?s Rally

SH @ the Bell: Wall Street Weakens at Week End

Buzz on the BullBoards



News Briefs

Kerkorian Cuts GM Stake To 7.8%
MarketWatch 18:47


Onyx Cancer Drug Cleared
TheStreet.com 18:41


Palm 2Q Earnings Advance On Tax Benefit
Associated Press 18:32


Nike Kicks Past Estimates
TheStreet.com 18:30


GM Skids To 18-Year Low
CNNmoney 17:51

MAGR
WEDX
CBLRF
CMKX
WXITF
LORFF

[moneyonstreet]

By: hughhefster
20 Dec 2005, 11:30 AM EST
Msg. 1457 of 1532
Jump to msg. #
Investment Highlights
Proprietary, patented, antigen based cervical cancer screening test under development using blood and other body fluids
Preliminary experimental results show assay to be substantially more effective than currently available tests
Only blood based product under development for cervical cancer screening
Ongoing US and international regulatory discussions
Experienced management team, board and active advisory board recruited
Additional products in pipeline and in-licensing activity underway
Discussion’s in progress with several acquisition targets

Additional Technology/Products

Oral Cancer Diagnostic Strip – The Company believes that its test strip can be modified to test for the many oral cancers attributed to HPV. This will be point-of-care product offered to dental professionals.

Short Term Goals

To develop multiple platforms for diagnosing cervical cancer and cervical cancer precursors.

AbReact™
Analyte Specific Reagents (ASR)

To be sold as an adjunct to existing technologies
QuickStrip™
Physician’s Office Test ELISA Tests
Ex-US routine test

Screen the 1.7 billion women who are underserved

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

[moneyonstreet]

Im Tal sind wir, wird Zeit daß wir den Berg hinauf klettern

[moneyonstreet]

the trend is your friend

[moneyonstreet]

der dritte hüpfer sitzt.... ausbruch

[moneyonstreet]

Press Release Source: Grant Life Sciences, Inc.


Grant Life Sciences Awarded Patent for Vital Components of Blood-Based Cervical Cancer Test
Thursday September 22, 4:51 pm ET
Patent Marks Major Company Milestone and Significant Step toward Product Commercialization


MURRAY, Utah--(BUSINESS WIRE)--Sept. 22, 2005--Grant Life Sciences (OTC Bulletin Board: GLIF - News) today announced that it was recently awarded a U. S. patent for essential components of its proprietary technology for diagnosing cervical cancer.
ADVERTISEMENT


"The issuance of this patent represents a significant milestone for Grant Life Sciences in our drive toward an effective, commercial blood test for cervical cancer and its precursors," said Michael Ahlin, the company`s vice president and founder. "Issuance is a validation of our original and ongoing work on cancer detection, and we can now progress more effectively and confidently toward further development and ultimate commercialization of our cervical cancer test."

The patent (Number 6,933,123) encompasses essential components of the company`s proprietary technology: "Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers."

Ahlin explained that cervical cancer remains the second most common cancer among women worldwide. For over 50 years, the Pap smear has been the most widely used method for screening for cervical cancer, but it has proven consistently inadequate for detecting the disease in its early, most curable stages. As a result, each year about 500,000 women worldwide are diagnosed with invasive cervical cancer, and more than 300,000 women die of the disease.

According to Ahlin, the overwhelming cause of cervical cancer (over 99% of cases) is infection by the human papillomavirus (HPV). The newly issued patent encompasses novel amino acid sequences, or small proteins, isolated from particular genetic regions of HPV types 16 and 18, which are responsible for most cervical cancers. These novel proteins developed by Grant Life Sciences function as probes in a more rapid, sensitive, and specific test for detecting or diagnosing HPV-associated cellular abnormalities, precancerous lesions, and cancers.

"There remains an urgent need for a comparatively simple, inexpensive and sensitive blood test for the early detection of cervical cancer," Ahlin stated. "We at Grant Life Sciences are proud and excited that we have been moving progressively toward meeting that need."

Ahlin noted that Institutional Review Board-approved studies at multiple medical centers are underway in the move to perfect and finalize the cervical cancer test.

About Grant Life Sciences Inc.

Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious, or economic reasons. Further information is available at: www.grantlifesciences.com.

Safe Harbor Statement Under the Private Securities Litigation Act of 1995

With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company`s operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company`s products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.



--------------------------------------------------------------------------------
Contact:
Grant Life Sciences, Inc.
Michael Ahlin, 801-261-8736
Vice President & Founder



--------------------------------------------------------------------------------
Source: Grant Life Sciences, Inc.

[Dauerpleite]

Was in Berlin los? Da handeln die schon mit 0,04€cent.

[Dauerpleite]

[posting]19.366.401 von Dauerpleite am 21.12.05 15:00:50[/posting]OHHHHHHHHHHHH "cent" ist zu viel geschrieben.

[stupidgame]

[posting]19.366.401 von Dauerpleite am 21.12.05 15:00:50[/posting]Ich wollt grad sagen, manche lernen es halt nie. 60% über pari gekauft. Was soll bitte der Blödsinn.

[Spitzenrolli]

Dann lies dir mal die News durch. Dann weißt du warum.
Das sind immer noch Schnapper Kurse...

[moneyonstreet]

uiuiuijuuuuuuuuuiii... das sieht guuuuuuuuuuuuut aus, der dritte hüpfer sitzt.... ausbruch!!!!!!!!!!!!!!!

http://stockcharts.com/gallery/?glif

[Micha2006]

hat jemand RT ??USA

[moneyonstreet]

rt 0,032

[estewe]

[posting]19.366.773 von Spitzenrolli am 21.12.05 15:14:25[/posting]welche news denn?

[Micha2006]

und steigts ?

[estewe]

0,03

[estewe]

0,027

[luto9]

,027

[estewe]

0,025

[loui2005]

rt 0,024 !

[Deggen]

RT?!

[estewe]

willst du nicht wissen

[estewe]

[posting]19.367.698 von Deggen am 21.12.05 15:55:44[/posting]0,023

[loui2005]

bid / Ask:

0,022 zu 0,023

[Deggen]

Danke!!!

[ollinbg]

Hallo!
Bin neu mit an Bord...

So langsam könnte es wieder drehen - was meint ihr?

[stupidgame]

[posting]19.366.773 von Spitzenrolli am 21.12.05 15:14:25[/posting]Dann lies dir mal die News durch. Dann weißt du warum.
Das sind immer noch Schnapper Kurse...

__________________________________________________________

Ja, und nu...?
Ich sag doch manche Leute lernen es nicht.
Hättet Ihr viel billiger haben können.

[ollinbg]

aks schon wieder auf 0,0261

[estewe]

wo stehen denn die news?

[jaxn]

ok, ab 0,021 nehm ich mir vielleicht welche

[flussaufwerz]

zu spät 0,04 kommt
bin bald weg
und tschüss

[jaxn]

rt?

[ollinbg]

rt:
0,023 0,024

[loui2005]

die armen, die heut ein Berlin zu 0,04 gekauft haben.

[ollinbg]

rt:
0,024 zu 0,026

[ollinbg]

rt

0,025 zu 0,027

[ollinbg]

rt
0,025 zu 0,026

seit 10min kein trade mehr...

[jaxn]

hab mich jetzt auch mal zu 0,025 hinreissen lassen.
schau ma mal.

[jaxn]

zock ich alleine, oder ist sonst noch wer dabei
wie siehts aus mit rt?

[ollinbg]

[posting]19.369.819 von jaxn am 21.12.05 17:41:26[/posting]Ich bin auch noch da

Im Moment tut sich herzlich wenig. rt 0,025 zu 0,0259.
Arca sitzt in LevelII mit ner großen Position im bid bei 0,022. Weiter sollte es deswegen meiner Meinung nach nicht runter gehen. Im aks schaut es eigentlich auch ganz gut aus. Wenn mal ein bisschen Kaufstimmung aufkommen würde, kann das wieder schnell nach oben gehen...

[jaxn]

is typisch.
jetzt haben die amies mittagspause.
is das selbe wie in D.
danach wird wieder kaufstimmung aufkommen.
also, entweder jetzt kaufen oder nie

[medom]

es zieht wohl wieder an

[ollinbg]

So, jetzt kommt auch auf levelII etwas mehr Bewegung rein.
Arca steht nun mit 2 anderen auf 0,023, nite und schb auf 0,024 im bid.
Im ask sind es 5 MM bis zur 0,03

[jaxn]

das ging dann ja mal voll in die hose.
wie könnts auch anders sein.

[ollinbg]

Naja, OTC eben - Übertreibung nach oben und nach unten.
Ohne News wäre ein weiterer Anstieg heute wohl kaum drinnen gewesen.
Aber da wird in Zukunft schon noch einiges kommen

[moneyonstreet]

[posting]19.372.979 von jaxn am 21.12.05 22:01:41[/posting]abwarten, gewinnmitnahmen (nur logisch nach 100 % plus) ... indikatoren abkühlen lassen, ende der woche sieht es wieder freundlicher aus.. und dann kommt new year schlussspurt.

[medom]

seh ich auch so, es kann nicht jeden tag 100% up gehen
ohne neue news, mal abwarten
gn

[ollinbg]

Was sind eigentlich - positver Newsflow vorausgesetzt - so Eure persönlichen Kursziele?

[moneyonstreet]

[posting]19.373.621 von ollinbg am 21.12.05 22:45:12[/posting]0,1 short
0,5 medium
1,0 arcoo long
5,0 arcoo megalong

[moneyonstreet]

bald richtig klingelingeling

GRANT LIFE SCIENCES INC Quick Quote: GLIF 0.02 (-0.01)




Traders Nation: Traders Nation Television -- "Happy Holiday`s from Traders Nation
12/21/05

Phoenix, Arizona, Dec 21, 2005 (M2 PRESSWIRE via COMTEX) --
Stocks covered throughout the show Traders Nation on (12.20.05) include: Grant Life Sciences Inc (OTCBB: GLIF) , Google Inc (NasdaqNM: GOOG) , Advanced Micro Devices Inc (NYSE: AMD) , PayStar Corporation (OTC: PYST), Sungold International Holdings Corporation (OTCBB: SGIHF)

Traders Nation Network and Traders Nation(tm), the largest syndicated "live" radio and television talk show for smallcap stocks under the parent company of Desert Son Media Corp., is please to wish the investment and trading communities a safe, warm holiday this Christmas season and a peaceful and prosperous New Year.

Kurt Schemers creator and host of Traders Nation says, "Thank you for making Traders Nation the preferred radio and television talk show for small to largecap stocks. We look forward in bringing our viewers and listeners nationally recognized guests, market commentary and winning trading strategies again in 2006."

The Traders Nation Network: TradersNation.com hosts a network of nationally syndicated financial radio and television talk shows through various forms of broadcasting methods. Daily, web site visitors, listeners, affiliates and financial content distribution companies are able to access the most up to date market news, alerts and overall market commentary.

The Show named "Traders Nation": Multiple segments make up the `LIVE` hour-long program where listeners and viewers gather daily to hear the latest smallcap news of the day and scheduled guests, from industry experts and CEO`s. Traders also share investing, trading strategies and potential hot stock plays swirl throughout the call-in portion of the show.

-- Traders Nation Television broadcasts through our partner Streetcast Television which is currently seen 4 days each week on America One Cable, a 24-hour broadcast network that provides programming to over 30 million households via 127 broadcast affiliate stations located in 40 states.

-- Traders Nation broadcasts are fed on the New York ABC`s Starguide Satellite System which can be received by over 4,000 radio stations across the United States. Our station affiliates capture Traders Nation for either a simulcast or rebroadcast of the show. http://www.tradersnation.com/program_clock.shtml -- Traders Nation is heard by tens of thousands of end users via QuoteStream online financial software.

-- Traders Nation is Apple`s iTunes only pre-select financial talk show listed.

-- TradersNation.com is the developer of ProXstream, a media player for the active trader. Traders can now access alerts, news, quotes, SEC filings, charts, free level II, and a variety of interviews and live radio talk shows that are fresh right from the Traders Nation studios. http://www.tradersnation.com/proxstream.shtml View and Listen At: http://www.tradersnation.com/radio.shtml Download Archive Information: http://www.tradersnation.com/store.shtml

Caller Line: 1-866-SMCAPPS / 1-866-762-2777

Be a Guest: http://www.tradersnation.com/contact.shtml

Other shows found on the Traders Nation Network: "The Stock Doctor" The Stock Doctor(s), Lee Siler, the Stock Evaluator, Steve Pizzuti, Johnny Bravo , John Dambrauskas, Brian "Bada" Bingham and Million Dollar Bill Keevan have been taking calls and giving investors their "Daily Stock Market Prescription" for over seven years. Starting as an hour a week, Sunday Noon-time advice show on a talk radio station in Orlando. Within three years they were live every weekday at noon on a dozen Florida radio stations. Then they were picked up to fill an afternoon spot on a national radio network. Callers from all across the country look for technical, fundamental and quantitative analysis from our colorful cast of characters. This isn`t your father`s call-in advice show. http://www.tradersnation.com/stockdr.shtml "Streetcast Television" Streetcast Television is an Television Broadcaster providing current financial news and content on the Equities Markets. The Streetcast Television broadcast is currently seen 4 days each week on the America One Network and has a viewing audience upwards of 500,000 respondents. http://www.tradersnation.com/television.shtml Disclaimer: We have not received any compensation nor do we have a current relationship with the following companies mentioned on Traders Nation: Grant Life Sciences Inc, Google Inc, Advanced Micro Devices Inc, PayStar Corporation, Sungold International Holdings Corporation.

CONTACT: Kurt Schemers, TradersNation.com Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2005 M2 COMMUNICATIONS LTD ********************************************************************** As of Saturday, 12-17-2005 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 11-02-2005 for AMD @ $23.40. (C) 2005 Comtex News Network, Inc. All rights reserved.

© 2005 Stockgroup Media Inc. | Disclaimer

[moneyonstreet]

hier mal eine long-stimme aus amiland... just my opinion

posted December 21, 2005 16:18
--------------------------------------------------------------------------------
Congratulations, Bullistic for making a profitable deal.
I got in at 0.020 and planned to hold it for
a few months. When it hit 0.029, I almost
tempted to take a profit. Then I considered
what`s up to the MMs and other factors: (a)
this is not a good time to make a rally --
too many investors wanted to get out for
tax purpose; (b) 0.03 is not a profitable
level for the MMs to make short sale later --
their av cost is 0.024; (3) the pr is not
out yet.
My conclusion is that the MMs have changed
the strategy to 2-stage rallies: the first one
is for those who wanted to get out and the
day traders. Yesterday`s rally is very healty
for GLIF. It allows the investors who got in
to build confidence because the pps did not
fall as last two Raalies. Most traders who
got out yesterday will appreciate the value
of GLIF and got back in again. I believe GLIF
will have a good support at 0.025 soon. The
top of next rally will be much higher.
Yesterday`s rally happened this way: The
first few deals were made among the MMs themselves.
These deals triggered some computer programs
which alerted the traders and BBS, which in
turn spreaded the msgs out. Pretty soon the
whole trading community all knew that GLIF was
on a run. This demonstrated all stock pps and
all rallies are contorlled by the MMs.
Yesterday`s small rallu is very good for
investors, too. Those who got out are winners
becasue they took profits and could invest in
some thing else. Those who are holding their
positions will stand to win bigger profins
when the second rally comes in a few weeks.
It will need 3 weeks to confirm my view
points. Thanks for your patience. JimSc

[moneyonstreet]

aus amiland.. erst werbetrommel rühren (radio and television talk show for smallcap stocks; s.o.) und dann

posted December 21, 2005 20:07
--------------------------------------------------------------------------------
Thanks for the information. 55 mm shares
were traded during the past 2 trading days.
This is very good for the expected PR
rally . If they could generate some rev
in next few Qs, GLIF will be a good gamble.
Right now it`s just another Otc stocks.

[moneyonstreet]

aus dem letzten q-filling:

Plan of Operations


We expect to acquire laboratory assets to augment our clinical research and development efforts and computer equipment and peripherals used in our day-to-day operations. Currently our only office is the office in Murray, UT, however the Company plans to consolidate its operations in Southern California during the fourth quarter of 2005.


In addition to 3 officers, the Company currently has one full-time employee and relies on a number of part-time scientific and business development consultants. During the next 12 months, we anticipate that we will add employees, including scientists and other professionals in the research and development, product development, business development, regulatory, manufacturing, marketing and clinical studies areas.


During the next 12 months, we plan to complete the development of our cervical cancer screening tests. We intend to continue to validate the effectiveness of the processes that we currently use in the tests we are developing through trials which will be conducted for us by third party testing laboratories. In the near term, we plan to meet with regulatory agencies in the United States and in other countries to determine the clinical trials and studies we will have to undertake and the data and other information we will be required to submit to them to support our future applications for authority to market and sell our planned cervical cancer tests in those countries . We also plan to begin studies and clinical trials in the United States and other countries that will be required in connection with our regulatory applications.

[medom]

#1085
aus welchem board?

[moneyonstreet]

von der glif-homepage:

...........................................

Short Term Goals

To develop multiple platforms for diagnosing cervical cancer and cervical cancer precursors.

AbReact™
Analyte Specific Reagents (ASR)

To be sold as an adjunct to existing technologies


QuickStrip™
Physician’s Office Test ELISA Tests
Ex-US routine test

Screen the 1.7 billion women who are underserved

....................................................

Investment Highlights
Proprietary, patented, antigen based cervical cancer screening test under development using blood and other body fluids
Preliminary experimental results show assay to be substantially more effective than currently available tests
Only blood based product under development for cervical cancer screening
Ongoing US and international regulatory discussions
Experienced management team, board and active advisory board recruited
Additional products in pipeline and in-licensing activity underway
Discussion’s in progress with several acquisition targets

[moneyonstreet]

[posting]19.378.954 von medom am 22.12.05 12:08:51[/posting]Allstocks.com`s Bulletin Board: GLIF ***Bouncing***

[ollinbg]

Stimmt schon, im Moment ist das Ganze ein reiner OTC-Zock. Kommt dann aber eine gute News, dann kennt der Wert auch kein Halten mehr. Solange heißt es hop oder top.

[ollinbg]

Denke aber, dass gerade Biotechs kommendes Jahr verdammt viel Beachtung finden werden und der große Renner werden.
Dann ist so ein kleiner Wert natürlich umso "explosiver".

[medom]

money thanks

[medom]

wird sogar schon auf xetra gehandelt, mh

[medom]

E*Trade hat im ask von 0,023 auf 0,026 hochgezogen

[jaxn]

das da was im busch ist, wird wohl jedem klar sein.
vielleicht schon heute die fortsetzung der rally.

[estewe]

scottrader nicht

[estewe]

bid ask 22 24

[giesser]

0.0195 glif - GRANT LIFE SCIENCES INC
Change:

High: 0.024

Low: 0.019

Volume: 682,625

war wohl eine Eintagsfliege

[giesser]

Detailed Quote Snapshot 12/22/2005 09:38 AM

0.0191 glif - GRANT LIFE SCIENCES INC

High: 0.024

Low: 0.019

Volume: 1,131,825

Quelle: http://www.pcquote.com/stocks/quote.php?symbol=glif

[estewe]

ja totalverlust

[medom]

giesser
geh deine blumen gießen

[giesser]

warum denn?

erfreue mich gerne an den verlusten anderer

[medom]

ich hoffe du versaust dir dabei nicht den bildschirm

[estewe]

[posting]19.381.678 von giesser am 22.12.05 15:44:23[/posting]wie krank ist das denn

haste sonst keinen spaß im leben ?

[jaxn]

scheiss otcbb

[Dauerpleite]

[posting]19.383.110 von jaxn am 22.12.05 17:01:54[/posting]Schimpf weiter, dann gehts hoch.

[jaxn]

dreck dreck dreck
hoffe es hilft

[moneyonstreet]

wenn gleich 0,022 fallen sollte, dann wird es heute grüner tag

[medom]

sieht so aus

[medom]

hat jemand rt

[moneyonstreet]

sk 0,0215, schwäche auf der zielgeraden

[moneyonstreet]

sk 0,0215, schwäche auf der zielgeraden

[medom]

danke

[moneyonstreet]

die trader sind wohl immer dabei.... rein/raus und viele sind dann mit 100 usd am tag zufrieden ... s. ende heute und 0,022 deckel.

GRANT LIFE SCIENCES INC Quick Quote: GLIF 0.02 (-0.00)




Stockguru.com: Guru Alerts for Thursday, December 22, 2005 BTYH, GLIF, CORG, FNIX.
12/22/05

Dallas, Texas, Dec 22, 2005 (M2 PRESSWIRE via COMTEX) --
Stock Guru Alerts for Thursday include Bad Toys Holdings, Inc. (OTCBB: BTYH), Grant Life Sciences, Inc. (OTCBB:GLIF), Cordia Corporation (OTCBB: CORG), and Fonix Corporation (OTCBB:FNIX).

To feature your publicly traded company in our alerts, email [e-mail] or call [phone] and we will gladly send more information on featuring your company with StockGuru.com.

Bad Toys Holdings, Inc. (OTCBB: BTYH) traded as much as 4.29% over open on Wednesday.

To view the Stock Guru Profile for Bad Toys Holdings, please visit: http://www.stockguru.com/profiles/btyh/ Bad Toys Holdings, Inc, (BTYH), participates in two distinct business segments.

Southland Health Services, Inc.

This division provides medical transportation services, including emergency and non-emergency ambulance services. Our Southland Division operates in over 200 communities within the following seven states: Mississippi, Alabama, Florida, Louisiana, Kansas, Tennessee, and Virginia. We operate in excess of 160 ambulances and wheelchair vans and have over 1,100 full and part-time employees. At our current run rate we will transport more than 130,000 patients in this calendar year.

Bad Toys Inc.

This division, Bad Toys, Inc., American Eagle Manufacturing Company and Gambler Motorcycle Company, continues to design, manufacture, distribute, service and sell custom made, Harley Davidson type, V-twin motorcycles from component parts. We also offer premium accessories, parts, customizing items and apparel related to Harley-Davidson motorcycles on-line and directly from our retail and factory outlets. This division participates in Sprint Car Racing products and custom car construction & restoration. The Company also offers brokerage services for custom cars & motorcycles.

For further information, contact Bad Toys Holdings, Inc., Larry N. Lunan, President and Chief Executive Officer, [phone] or Al Kau, Investor Relations in California at [phone]. Further information about the Company may be obtained on its website at www.badtoys.net.

Grant Life Sciences, Inc. (OTCBB:GLIF) closed down at 25.00%, trading 15,279,432 shares on Wednesday.

Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.

Cordia Corporation (OTCBB: CORG) traded as much as 12.61% over open on Wednesday.

Cordia Corporation develops and provides industry specific applications, solutions and services. Cordia`s primary operations are currently concentrated in the telecommunications industry through its operating subsidiary, Cordia Communications Corp. In addition to retail and wholesale telecommunications services, Cordia also provides a suite of proprietary Web-based software and outsourced services it refers to as "UNE-P in a Box" that permit competitive local and long distance telecommunications providers to rapidly introduce local and long distance services.

Fonix Corporation (OTCBB:FNIX) closed down at 8.70%, trading 7,614,961 shares on Wednesday.

Fonix Corp., based in Salt Lake City, is an innovative communications and technology company that provides integrated telecommunications services and value-added speech technologies through Fonix Telecom Inc., LecStar Telecom Inc. and The Fonix Speech Group. The combination of interactive speech technology and integrated telecommunications services allows Fonix to provide customers with comprehensive cost-effective solutions to enhance and expand their communications needs. Visit www.fonix.com for more information, or call 801-553-6600 and say "Sales."

About StockGuru.com:

StockGuru.com features daily alerts going out three times daily to members. To join our email alert list, please visit: http://www.stockguru.com/stocks.htm To feature your publicly traded company in our alerts, or to discuss our complete services, please contact: John Pentony at [phone]. Our services include our Morning, Midday and After The Bell News Releases. Additionally we Profile publicly traded companies on our web site, we do interviews with CEO`s or other key executives on our web site, and we have our financial writers cover our companies.

Those interested may also email: [e-mail] and we will gladly send more information on featuring your company with StockGuru.com.

Stockguru.com ("SG") provides its members with the latest news, press releases, and research reports for all the companies highlighted on the site. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements.

Disclosure: Bad Toys Holdings, Inc. (OTCBB: BTYH) Pasadena Capital Partners and its affiliates have been compensated $48,000 and 125,000 restricted 144 shares for profile coverage. Neither Pasadena Capital Partners, nor it affiliates are registered investment advisers or broker/dealers. Pasadena Capital Partners makes no recommendations that the purchase of securities of companies profiled in this Web site is suitable or advisable for any person or that an investment such securities will be profitable.

CONTACT: John Pentony, Publisher Tel: [phone] e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2005 M2 COMMUNICATIONS LTD

[medom]

so bin jetzt bis dienstag auf familienbesuch (kein internet ), passt mir auf die kleine (große)glif gut auf.
wünsch euch frohe weihnachten

[moneyonstreet]

now starting level II of breakout after two day accumulation.. we will see tommorrow

[moneyonstreet]

target 0,04 to years end 2005
target 1,00 to years end 2006

==>> a bet of a hot otc-stock

[moneyonstreet]

in amiland there are some people with greater target

By: agabilo74
22 Dec 2005, 04:12 PM EST
Msg. 1748 of 1748
(This msg. is a reply to 1743 by guinto.)
Jump to msg. #
guinto sure its not merk and thats why i am invested here and not in merk and co. If GLIF has success than everything is possible not only $5 . But i know what you want to say.
For now we must look for the progress GLIF makes to build their product and there is a risk as long as the product is not to buy!But when everything goes good and if the product is a success than nothing is inpossible and than we could talk about how long GLIF will take to hit $30.
But if someon can give me the answers for " IF " and "when" than I offer him a job with 1 million a year.

Yes you are right $5 is a dream for now.



recht hat er, this good boy, if and when... you can dream.. make your own dd (not easy), hear to the insider and the mm-music .

[moneyonstreet]

glif share is coming..... great buuuuuuuummmmm kommt näher

[moneyonstreet]

der dritte anlauf sitzt... think about it

[moneyonstreet]

von der glif-homepage:

...........................................

Short Term Goals

To develop multiple platforms for diagnosing cervical cancer and cervical cancer precursors.

AbReact™
Analyte Specific Reagents (ASR)

To be sold as an adjunct to existing technologies


QuickStrip™
Physician’s Office Test ELISA Tests
Ex-US routine test

Screen the 1.7 billion women who are underserved

....................................................

Investment Highlights
Proprietary, patented, antigen based cervical cancer screening test under development using blood and other body fluids
Preliminary experimental results show assay to be substantially more effective than currently available tests
Only blood based product under development for cervical cancer screening
Ongoing US and international regulatory discussions
Experienced management team, board and active advisory board recruited
Additional products in pipeline and in-licensing activity underway
Discussion’s in progress with several acquisition targets

[moneyonstreet]

if and when....

By: mosdef99
22 Dec 2005, 08:09 PM EST
Msg. 1754 of 1761
(This msg. is a reply to 1743 by guinto.)
Jump to msg. #
guinto, this stock currently has 150 mil a/s which is nothing in this industry. Bio-tech/pharma companies trade at serious multiples, so this company could easily be valued at $500mi-$1bil on forward looking revs when they start marketing the cervical cancer test, which would be purchased year after year, as it is an annually needed test for women worldwide. Thus, even if the company raised their a/s to 250mil shares, this could trade $2.50+ easily. Check out the value of most biotech/pharma that don`t even have products on the market yet.

[jaxn]

es is zwar noch nix in trockenen tüchern...
aber der nächste mega zock kommt bestimmt.
braucht nur eine klitzekleine news...
und bummmmm
obs noch dieses jahr sein wird..
man wird sehen.

[moneyonstreet]

grüne woche sk 0,021 bid 0,021 / ask 0,023

allen investierten und interessierten

[moneyonstreet]

so richtig schön gemütlich mit den liebsten



und am zweiten weihnachtstag viel schnee

[arcoo]

http://www.reuters.hu/card_dom/index_content.html

[arcoo]

http://www.reuters.hu/card_dom/index_content.html-----------… weinachten

[arcoo]

frohe" target="_blank" rel="nofollow ugc noopener">http://www.reuters.hu/card_dom/index_content.htmlfrohe weinachten

[arcoo]

WATCH GLIF GET BULLISH TOMMORROW.EOM

[medom]

ich hoffe heute, und nicht morgen

[arcoo]

medom warum hast zufiel ausgegeben zu weinachten schöne grüße arcoo

[medom]

money
slwf wär doch nicht sooooooo schlecht gewesen

[jaxn]

oh je
hoffe die 0,015$ halten.

was für eine klitsche tsss

[jaxn]

der hype vor ein paar tagen sollte wohl das letzte zucken gewesen sein.
fuck fuck fuck

[arcoo]

was für wörter geduld ist eine tugend ein guten rutsch und ein schönes glif 2006

[arcoo]

http://www.thehpvtest.com/

[estewe]

[posting]19.432.575 von jaxn am 28.12.05 16:03:59[/posting]hab´s mir doch gedacht ein neuer name im glif-thread

der letzte übriggebliebene vom mini-hype zu welchem preis hast du dich denn eingekauft ?

[estewe]

nix gegen dich jaxn aber is schon erstaunlich wie sie alle nach den trader-alerts aus den versenkungen kamen

da wird von news gefaselt und mal schnell 4 Euro-Cent zum Schnäppchen erklärt
das übliche gepushe eben

aber eigentlich egal zu welchem preis du eingestiegen bist kneiff die backen und gib glif bis mitte 01/06 ne chance

jammern nutzt nix

[arcoo]

!!!!!!FREITAG!!!!!!

[arcoo]

LEVEL" 2 ASK ist nicht viel bis jetzt ist mir gestern schon aufgefa...

[jaxn]

[posting]19.436.355 von estewe am 28.12.05 19:57:41[/posting]ja...
sch.. alerts
hab leider zu 0,025$ gekauft.
hab mir schnell intraday einen gewinn versprochen.
jetzt muss ich wohl gezwungener massen halten.
die MM können solche systeme zu sehr manipulieren.
hoffe doch das sich jetzt ein boden ausbildet.
dabei hab ich schon zuerst einen kaufauftrag zu 0,020 gehabt und in meiner blinden gier schnell gelöscht.
na ja... sind wir mal im eigenen interesse optimistisch.
dausend....

[jaxn]

mal ne kurze frage, jetzt wo ich an das teil gekettet bin.
was versprecht ihr euch von der bude?
was wäre denn für euch eine breaking news?
und wann würdet ihr das teil raushauen?
würde mich gerne ein wenig schlau machen.
vielleicht finde ich auch noch was raus.
na ja..
auf das glif jahr 2006

[arcoo]

zu erst ist das teil wie du sagst kein teil sondern eine gold taller wie du so auch wir warten auf die news das glif die erst und das beste zur bekäf.krebs und eigende blood test mehr möchte ich nicht sagen alles zum lesen hier und alles kann nichts muß 0,10 -?????? ich liebe die firma sie hat das etwas um es zu volend nur warten ist eine tugend investieren nicht zocken

[jaxn]

mal sehen...
wenn es stimmt haben die 58.389.113 shares
das wäre eine MK bei 0,019$ von 1.109.393$
laut quartalsbericht vom 14.Nov.2005 :

During the next 12 months, we plan to complete the development of our cervical cancer screening tests. We intend to continue to validate the effectiveness of the processes that we currently use in the tests we are developing through trials which will be conducted for us by third party testing laboratories. In the near term, we plan to meet with regulatory agencies in the United States and in other countries to determine the clinical trials and studies we will have to undertake and the data and other information we will be required to submit to them to support our future applications for authority to market and sell our planned cervical cancer tests in those countries. We also plan to begin studies and clinical trials in the United States and other countries that will be required in connection with our regulatory applications.

Under the licensing agreement with Accudx we are beginning to take orders for rapid tests for Malaria and Dengue Fever, and should have sales revenue commencing in the fourth quarter of 2005 . The establishment of sales and marketing channels positions the Company for the eventual manufacturing and distribution of our core product, the immunological serum-based test for detecting Cervical Cancer.

As of September 30, 2005, we had total current assets of $1,291,490 and total current liabilities of $537,868.

könnte vielleicht wirklich sehr explosiv werden,
wenn man die niedrige MK von 1,1Mio € betrachtet.
klappt das mit der entwicklung des krebs tests dann geht hier tatsächlich die post ab.
schau ma mal.

[jaxn]

chart deutet auch auf eine bodenbildung bei 0,015-0,020 hin.
auch die bollinger sind schon schön eng.
denke mal ich hätte meine sicher billiger bekommen, aber am ende komme ich auch noch zu meiner kohle.
irgendwann sehen wir bestimmt intraday wieder die 100% plus.
good zock,
J

[arcoo]

es ist scheiß egal ob du zu 0,02 oder zu 0,50 gekauft hast auf langer zeit ist GLIF ein sieger

[jaxn]

[jaxn]

wird wahrscheinlich bei 0,016 heftig rebounden.
ist leider ein gap entstanden bei 0,0164.
also....
bei 0,017 alles absorbieren.

[arcoo]

gut..Last Trade: 0.0194
Change: 0 ("0.00%")
Previous Close: 0.0194
Open: N/A
Day`s Range: N/A-N/A
52wk Range: 0.04 - 1.40
Volume: 0
Market Cap: 1.8M wir sind unter der 52wk range allso

[medom]

wir werden heute und morgen sehen wo es hingeht,
wobei es heute vielleicht noch keinen großen ausschlag
geben wird. die ca. 40 mil aktien die bei dem 80% anstieg gehandelt wurden sind mittlerweile fast schon wieder verdaut, und wir stehen über dem damaligen stand (vor dem 80% anstieg) von 1,5 cent. für mich eingutes zeichen, zumal wir nicht vergessen dürfen das seit 8.11.05
keine news mehr heraus kam. die 1,8 cent scheint eine fette unterstützung nach unten zu sein. sollten positive
news kommen habt ihr ja schon gesehen was da passiert.
arco noch ein tip verliebe dich nicht in eine aktie,
da gibts andere dinge zum verleiben
wenn ihr kauft solltet ihr in usa kaufen dort wird der preis gemacht.
auf einen grünen tag

[arcoo]

medom ich liebe mein ganzes depo alle meine kinder sind mall groß

[arcoo]

GLIF will find those women who are HPV pos. and MRK will treat them with their new vaccine! We are looking at hundreds of millions of $$$ world wide and maybe billions. http://abcnews.go.com/Health/wireStory?id=1292471

[arcoo]

es ist viel $$ wenn es heraus ist blood test die geduld ist was longs belohnt wird----------Nov 8, 2005 — By Ben Hirschler

NEW YORK (Reuters) - Merck & Co. Inc. is confident its new cervical cancer vaccine Gardasil will win a positive recommendation from a key government group that sets standards for immunizations, a company president said on Tuesday.

Gardasil is on schedule to be filed for marketing approval with the U.S. Food and Drug Administration before the end of the year but its commercial success also hinges on the view of the Advisory Committee on Immunization Practices, or ACIP.


Would You Donate Your Face for a Transplant?
Buzzed Driving Is Drunken Driving
Eat Your Spinach!

Margaret McGlynn, president of Merck`s vaccine division, told the Reuters Health Summit she expected an endorsement from the group — which sets standards for doctors, insurers and the public funding of vaccines — shortly after FDA approval.

"We have no reason to believe, on the ACIP, that we will have anything but a positive recommendation. They are very enthusiastic about the vaccine," she said at the summit, held in New York.

Gardasil is the first in a new class of vaccines targeting a sexually transmitted infection called human papillomavirus (HPV) which causes most cases of cervical cancer, the second-biggest cancer killer in women.

McGlynn said an ACIP green light could come shortly after any FDA decision to approve the product.

"It can happen weeks after," she said. "They do need to wait for FDA approval but all indications are that they will review this as quickly as possible."

GLAXO AS RIVAL

Britain`s GlaxoSmithKline Plc also has a late-stage experimental HPV vaccine, called Cervarix, which is further behind Gardasil in development.

The products are among the most closely watched in the two companies` portfolios, reflecting the scale of the potential patient market they are addressing, which Merck estimates could total 75-80 million in the United States and Europe alone.

Glaxo believes the total market for cervical cancer vaccines could be worth $4 billion to $7 billion in annual sales by 2010.

McGlynn said the overall market for the rival vaccines was clearly "tremendous" but Merck would have a first-mover advantage that should allow it to tap into initial strong demand.


Continued
1. 2. NEXT»

Print This StoryPrint This Story E-mail This ArticleEmail This Article RSS Headlines Newsletters

[jaxn]

[posting]19.442.809 von arcoo am 29.12.05 13:56:20[/posting]halt uns am laufenden wie das LEVELII aussieht.

[arcoo]

also bis 0,03 ist platz bei volum....danach muß man sehen news werden doch bald erscheinen spä... januar 2006

[jaxn]

zur abwechslung mal grün.
hätte nix dagegen wenn es eine sylvesterrally geben würde.

[medom]

guten morgen

BUY-IF

0.0210
+0.0016 +8.25%

Candlestick Analysis
Today’s Candlestick Patterns:

High Wave
Bullish Tri Star

[arcoo]

wo ist acra ist nicht mehr auf level 2 das ist gut

[arcoo]

ups er ist da aber kauf 500 und sell 200

[arcoo]

0,02 ist fest

[arcoo]

" target="_blank" rel="nofollow ugc noopener">http://stockcharts.com/def/servlet/SC.web?c=glif

[medom]

wünsche euch ein gutes und grünes 2006

[arcoo]

GLÜCKLICHES NEUES JAHR zu allen GLIF-Halter!

[moneyonstreet]

guten Rutsch in das neue jahr von money und dem n-team

http://www.neckermann.de/index1.mb1?mb_f020_id=b_8pH50p2Eygb…

2006 will be glif year
0,1 is coming



kfr. aufwärtstrend muß halten... dann durch 0,03 durch ... than we are on the bullish side

[arcoo]

morgen und ein schönes 2006 die woche müßte ja die 0,03 %%%%1 springen es wird heiß ab jetzt

[arcoo]

Im neuen Jahr
das alte war nicht immer nett,
mit Showtime und mit Guten morgen,
mit Worschtpaket und Geld sich borgen,
mit Gekeife und Gezanke,
wenn auch nur selten, dafür danke,
viel ist passiert im alten Jahr
und es war gut so wie es war,
doch alles hat einmal ein Ende,
und es wird Zeit für eine Wende,
zum Besseren und zum Neuen hin,
denn da ist meistens Power drin
und den Leuten mit Niveau,
rufe ich zu macht weiter so,
denn ohne euch ist jeder Thread,
langweilig und wenig nett,
drum hoffe ich im neuen Jahr,
wird alles besser als es war
und ich glaube fest daran,
wir haben Glück mit GLIF

[arcoo]

2006$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$2006$$$$$$$$$$$$ BIO:
Stan Yakatan, MBA, is Chairman and CEO of Grant Life Sciences, Inc. He has over 30 years experience as a chief executive, entrepreneur, and operational manager for biotech and medical companies. He served as an executive and in several instances as CEO with New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific and Biosearch. He has founded or co-founded more than 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He sits on the board of directors of several public and private companies, and has served as an advisor to a number of the world`s leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada) as well as to the governments of Australia and Canada.

Company Profile:
Grant Life Sciences, Inc. develops products to improve the efficiency of diagnosing cervical cancer. The Company is developing protein-based screening tests to screen woman for cervical cancer and pre-cancerous conditions. These screening tests analyze blood for the presence of certain antibodies that appear only when cervical cancer or certain pre-cancerous conditions are present. Invasive cervical cancer kills approximately 300,000 women annually world-wide. There are more than 120 million cervical screening tests administered annually in the United States and Europe. But more than 120 million eligible women 20+ years old in developed nations still do not get Pap smears. Globally, more than 1.7 billion women over the age of 20 do not undergo any cervical cancer screening.

CEOCFOinterviews: Mr. Yakatan, please give us a little background on Grant Life Sciences.
Mr. Yakatan: “The technology behind Grant was begun over two years ago when a scientist from China, working with the University of Utah, teamed up with Dr. Mark Rosenfeld to do some work in cervical cancer. As a result of their initial activities they filed a patent for the use of various amino acids to identify the antibodies that surface when a woman has cervical cancer. They looked at blood and body fluids as opposed to the traditional Pap smear. With their patent applied for, they connected with a local entrepreneur named Michael Ahlin, who today is our Vice President of Development and a Director with Grant, and he provided some initial capital. When the venture capital route proved to be too dilutive, they began working with a brokerage firm here in New York to facilitate a reverse merger with a publicly traded entity to raise capital, which was done quickly and successfully. Then I and several others with a lot of experience were recruited to be the management team, which is where we are today.”

CEOCFOinterviews: What is it that your test can do that others can’t?
Mr. Yakatan: “Normally to check cervical cancer, women generally go for a Pap smear, which is considered in the industry to be highly inaccurate. Currently, there is no simple test, where you can just take the blood from a patient and determine by measuring antibodies in the blood whether cervical cancer or cervical cancer pre-cursors are present. We have developed what we believe is the first blood test that does this, and the initial data is extremely compelling.”

CEOCFOinterviews: What is it that your scientists have discovered that hasn’t been done before?
Mr. Yakatan: “We’ve discovered in the literature five or six attempts to identify precursors to cervical cancer through various methods. What our group did is developed a series of oncogenic amino acid sequences. We have characterized them in a way that can be utilized in a standard screening test where the amino acid sequences would truly identify the presence of cervical cancer or cervical cancer pre-cursors in blood or bodily fluid samples. I don’t think it’s any trick or black magic; I think that we’ve just been able to do a lot of laboratory work in terms of screening hundreds of different amino acid sequences. We have discovered that a test that we would make for the U.S. market may have a different sequence than a test that we would make for the Indian or Chinese markets because the makeup of the oncogenes that show cervical cancer activity vary in different geographical areas of the world. What we are doing now is working very closely with a partner, Allogen, which is a part of the Cleveland Clinic Foundation, in trying to characterize all of these amino acids. We think that within three to six months, we’ll be able to have our initial characterization completed and a product essentially ready to go into clinical trials, both in the United States and in other places in the world.”

CEOCFOinterviews: What’s the process and about how long does it take?
Mr. Yakatan: “We think that the longest process for us is the amino acid characterization. What we want to do is a sample collection before we go to any regulatory agency; we then test these samples from thousands of patients in what we call institutional review board programs. We have a few of them already set-up at USC, UCLA, Johns Hopkins and a local hospital in Utah. We’ve begun an active program to identify 4,000 samples within a six-month period to do the characterization program. So we think it may take two to three months to characterize the amino acids; another four to six months to do the sample collection and process those samples. Then we would begin a regulatory submission. If we are lucky, and I say lucky is the key word, we will be able to file a 510K with the US FDA (Food and Drug Administration) as an adjunct to Pap smears and that process could take three to six months. However, if we have to do a complete product disclosure process, it could take as much as eighteen months to two years. We believe that in the rest of the world we can get a swift approval of our rapid test. We think that once the nine months to a year of laboratory development time and amino acid characterization is completed, we could put a product on the market outside of the U.S. within a year.”

CEOCFOinterviews: Where do you go from here?
Mr. Yakatan: “We’re continuing to characterize the amino acid sequences to make sure that we have the right sequences. We are currently developing two products, the first of which is an ELISA (Enzyme Linked Immunosorbent Assay) test which we would file as an adjunct in the United States through the FDA. The second is a rapid test-- a point-of-care test that would be low cost and could serve the more than 1.7 billion women outside of the United States and Europe who normally don’t get any type of cervical screening. This probably accounts for over half the world and can be due to religious or economic reasons or just some type of taboo where women don’t feel comfortable getting a cervical exam from a physician.”

CEOCFOinterviews: Is there a market for rapid test in the United States?
Mr. Yakatan: “The issue is how imbedded the Pap smear is in the U.S. and whether or not we would be able to get the community to accept a blood test after 50 years of doing traditional Paps. In our early discussions with people in the marketplace as well as the FDA, it’s been suggested to us that the best way to get a new cancer test approved is as an adjunct. So, we think that strategically it makes sense to develop an adjunct test for the U.S. market and develop an inexpensive rapid test for the global market.”

CEOCFOinterviews: Do you have enough funding going forward?
Mr. Yakatan: “Our initial capitalization was through a reverse merger were we raised about $1.8 million total. We are now looking for another $3 to $5 million and we think that with that second round of financing, we should be able to complete all of the pre-market activities and get the products on the market.”

CEOCFOinterviews: What is the market potential for your test?
Mr. Yakatan: “In the United States, there are 60 million women who receive routine Paps of some form. Out of that, about 20% get false positives or false negatives, which lead to about 9 million colposcopy procedures; of that, 7 million turn out to be negative. So, we want to focus on an adjunct test where we could reduce the number of colposcopies and save the American health care system over $1.5 billion annually, not to mention eliminating the unnecessary mental anguish some of the false negatives create for our mothers and daughters. We think that the U.S. market alone is about 7 to 10 million tests annually at $25.00 to $30.00 a test. As I said before, the world market outside of the U.S. consists of over 1.7 billion women that have never been screened. We think that for those women, we can develop a test that would cost under $5.00, which is our goal. Then, we would ultimately put that same test on the market in the United States. I was retired for many years from being a CEO in biotech and when the opportunity came to me to look at a novel patented technology that serves an unmet market of over 1.7 billion people, that was enough excitement to get me to come back to work again.”

CEOCFOinterviews: Can you give us an idea of what you are up against in the medical community to gain acceptance for your new approach?
Mr. Yakatan: “The issue is that Dr. George Papanicolaou developed this test about 68 years ago. If you talk to any medical pathologist they will tell you that this is an archaic test that is highly inaccurate. However, it has become well accepted in the community. It is completely reimbursed by the insurance community and if they get a false positive, the patient would then go for a colposcopy, another reimbursable procedure. Unfortunately false negatives are more problematic of course. Just to give an idea of how well entrenched the Pap smear is in the United States, there was a recent article in the N.Y. Times that pointed out that about 12% of the women receiving Pap smears have had hysterectomies. They don’t even have a cervix any longer to take a Pap sample from!. Our new medical director, David Bolick, MD, FCAP, MIAC, is one of the most well-known spokesmen in the world for the replacement of the Pap smear. It’s one of the reasons we brought David into our fold and he will be speaking at meetings all around the United States on our technology.”

CEOCFOinterviews: What about going directly to women and women’s groups?
Mr. Yakatan: “We plan to do exactly that. One of our founders, Michael Ahlin, has been given the responsibility to look into women’s groups around the United States and see if we can generate support. It is common knowledge among the medical community that the current process of the cervical examination a very negative and highly invasive experience.”

CEOCFOinterviews: Could you address potential investors; what should they know about the background of the management and the company that would make them want to invest it Grant Life Sciences?
Mr. Yakatan: “We have a very experienced management team. I have 35 years of experience in the biotech world. There are people who consider me part of the old guard. I’ve run companies like this before and much of the investment community knows who I am and my track record. We have a CFO, John Wilson, who has a similar background and a strong financial pedigree. He was senior banker at Credit Suisse First Boston and prior to that, served as CFO for Hardee’s Food Systems, Perrier USA and Bell Canada International. John has served on numerous boards, both public and private. In many of these cases, he was their CFO and did tremendous things for them. We have someone who has 20 years experience in product development ready to join us. In diagnostics we are working with the man who actually developed the rapid test program for Hoffmann-La Roche in terms of developing our rapid test program. We are working directly with the cancer center in China and that’s important because China has the highest incidence of cervical cancer in the world. There are approximately 100,000 deaths there a year because of the lack of screening and we are the only company that is working directly with the center. One of our founders, and a continuing consultant to the Company, is a scientific advisor to the center in China and has about ten years experience in the Chinese market. We brought on as a consultant to the company a former high level executive at the National Cancer Institute and he is working with us in terms of government funding and grants. We believe that within the next 2 to 3 months we will solidify a major relationship with an institute in the United States that has the largest W.H.O. grant in the world for this type of work. So, we think that the combination of the experience of the management team, plus the market size and viability of the market are excellent opportunities for investors.”

CEOCFOinterviews: In closing, could you tell us how long do you anticipate it will take for acceptance?
Mr. Yakatan: “The acceptance will be very rapid. We’ve actually had discussions with the Gates Foundation and other organizations that specialize in finding funding for third world countries and we are just in the early stages of those discussions. In reality, the company as it exists now is essentially two months old. The management team has worked very closely with the founders to pull together all the work that has been done to date and that has been a harmonious relationship.”

[jaxn]

ein saulangweiliger otc wert

[arcoo]

aber der hammer wenn die zeit kom...

[arcoo]

ich denke es wird hochschieben wann aber bald

[jaxn]

[posting]19.517.782 von arcoo am 03.01.06 17:44:12[/posting]ich zock ja eh mit.
würde mich halt freuen wenn es hier mal konkurrenz zur abacho geben würde.
im moment ist halt noch tote hose.
jetzt will ich aber auch mal einen intraday 1000er mitmachen.
na ja.
ich habs befürchtet das das gap noch geschlossen werden muss damit die MM den nächsten mega zock vorbereiten.
wie sieht es eigentlich auf level 2 aus?

[jaxn]

tja..
entweder gap schluss oder ATL.
wir werden sehen.

[arcoo]

was ist atl anton tanzt lambada

[giesser]

All Time Low

Allzeittief

und es wird noch tiefer gehen.

mein sagen seit 3 monaten

[jaxn]

[posting]19.533.037 von giesser am 04.01.06 18:10:28[/posting]auf lange sicht ist das ding wahrscheinlich zum untergang verdammt.
aber unterschätze nicht die macht der MM manipulatoren.
ich tippe auf weitere heftige ausschäge.
in der zwischenzeit zock ich mit denen mit.
ich bin mir fast sicher dass es bei 0,016 wieder ordentlich knallen wird.
vorher wird sich eher wenig bewegen.
aber die teile zu 0,016 bekommen sowieso nur die MM
wenn man glück hat bekommt man noch welche zu 0,017
den rest werden sich die haie ausmachen

[jaxn]

der mutige beginnt also langsam einzusammeln.

[estewe]

[posting]19.532.411 von arcoo am 04.01.06 17:27:31[/posting]

da isser ja der giesser, na geht dir wieder einer ab weil glif unter 2 cent steht.

[estewe]

weißt schon, am leid der anderen erfreuen und so ..

[arcoo]

gisser du teekanne deine spruch klasse mein e mutter teresa ich liebe dich du mausebär du schlimmmmer finger

[fs2003]

[moneyonstreet]

kommt da etwas

[moneyonstreet]

schließen wir ein gap
wenn ja, welches zuerst

Open Gaps

Direction....... Date....... range
up........ Dec-20-2005.... 0.0165 to 0.0176
down.... Aug-04-2005.... 0.085 to 0.08
down.... Aug-03-2005.... 0.101 to 0.1
down.... Aug-02-2005.... 0.13 to 0.1255
down.... Jul-22-2005.... 0.14 to 0.13
down.... Jul-11-2005.... 0.145 to 0.14
down.... Jun-24-2005.... 0.27 to 0.241

[jaxn]

jetzt sieht es schon wieder wesentlich besser aus.

auf TH geschlossen

[jaxn]

[posting]19.557.112 von moneyonstreet am 05.01.06 23:05:53[/posting]mir reicht das erste down gap fürs erste

down.... Aug-04-2005.... 0.085 to 0.08

[moneyonstreet]

[posting]19.557.871 von jaxn am 05.01.06 23:39:06[/posting] 2006 will be GLIF-year

0,1 is coming

gap is gap (perhaps listen to o/s)
financing-shares are absorbed
revenues from rapid-test accu-dx should going on
finishing cervical-cancer-test will be the major-goal

[jaxn]

[posting]19.558.079 von moneyonstreet am 05.01.06 23:50:18[/posting]yeah.
lets make money
just pick it up from the street

[jaxn]

and i thought i could pick up some more shares at 0,017.
but what the hell.
if it wants to go now north i ll say its ok

[moneyonstreet]

[posting]19.558.253 von jaxn am 06.01.06 00:03:05[/posting]perhaps you will get it, i`m not sure that you`re sucessfull. time will show us the fully glif-story

[arcoo]

he mony das erste ziel ist 0,065 und dann weiter norden die ? kommt

[arcoo]

Kaufen-wenn


0.0220
+0.0030 +15.79%

Analyse Candlestick
Heutige Muster Candlestick:

Weißes Schließendes Marubozu
Bullish Versenken

[jaxn]

komm schon glif nur ein kleines plus heute und wir bekommen ein buy confirmed.
das sollte doch leicht machbar sein.

[Dauerpleite]

[posting]19.574.196 von jaxn am 06.01.06 19:11:50[/posting]z.Z. tut GLIF sein bestes. BID 0,025 ASK 0,026

[jaxn]

jaaaaa

die rakete startet.

[moneyonstreet]

[posting]19.576.511 von jaxn am 06.01.06 20:38:35[/posting]sk 0,17 (gap-closing) oder 0,025

denke eher wird 0,025

treibstoff für rakete

[moneyonstreet]

so ist es richtig

sk 0,0 17 (gap-closing) oder 0,025

denke eher wird 0,025

treibstoff für rakete

[jaxn]

da wird sicher ein buy confirmed draus
montag wirds knallen.
das werden jetzt die MM so hinmanipulieren.
die wollen noch ordentlich kohle machen.
die frage ist nur noch ....
wollen sie die 0,032 knacken oder reicht es ihnen jetzt.
was glaubt ihr?
ich meine man wird jetzt versuchen mehr draus zu machen.
alles gute noch für nächste woche.
daumen drücken
greetz,
J

[Dauerpleite]

SK 0,021
Volume: 5,622,272

[moneyonstreet]

friends, laßt euch nicht verarschen, just the beginning for glif-run...

follow the great money

don`t worry about shorting at intraday-end, just a bluff... make fun for shorties next week

[moneyonstreet]

arca have fun today with 0,026 on the ask side

arca bid at 0,016 was no problem. no shares got

and next week

wait and see

[moneyonstreet]

watch it out

show on the chart

make your dd

leichtes handicap durch mm-manipulation at the end heute... sonst noch viel mehr bullish

buuuuuuuummmmmmmmmmmmmmmm kommt näher... step by step up is the goal for longies and not traders... nach buuummmmmmmm kommt häufig oooooooooooohhhhhhhhhhh... lieber step by step

[moneyonstreet]

wer lust hat schaut mal rein... sind wir unten oder oben

http://www.wertpapier-forum.de/index.php?s=8a0cc6e858cb3720d…

[moneyonstreet]

have a nice we...

relax



next week watch glif-share.. sell, hold, buy... that`s the question... i have my answer

[moneyonstreet]

for medom... slwf-----geht da noch was oder

Seamless WiFi:
Wachstumsturbo vor Turnaround?!
Fortschritte an allen Fronten meldet unsere Empfehlung vom 10.August 2005, Seamless WiFi (WKN: A0ERQP). Die Umsetzung der Wachstumsstrategie wird durch ein hohes Umsatzwachstum, den planmäßigen Ausbau des Geschäftes und möglicherweise bevorstehende Akquisitionen immer deutlicher. Allein die Aktie honoriert den rasanten Wachstumskurs des Unternehmens bisher nicht im Geringsten…

Bei Seamless WiFi stehen alle Zeichen unverändert auf Expansion, auch wenn der Aktienkurs zuletzt eine krasse Abwärtsbewegung erlebte. Dies bietet spekulativ orientierten Anlegern jetzt wieder eine günstige Einstiegschance: Im Schlussquartal 2005 hat Seamless nämlich mächtig Gas gegeben und wichtige Weichenstellungen für die Zukunft getätigt. Die Früchte hieraus sollte das Unternehmen schon bald ernten können.

Eine der wichtigsten Nachrichten der vergangenen Wochen war sicherlich der schneller als erwartet und erfolgreich abgeschlossene Betatest von Seamless WiFis Phenom-Sicherheitssoftware bei IntentMediaWorks.com, einem der weltweit führenden Distributoren von autorisierten Downloads digitaler Medien. Als Folge dieses erfolgreichen Betatests hat IntentMediaWorks.com die Software lizenziert und wird damit zu einem wichtigen Referenzkunden für die Seamless-Tochter Seamless Peer2Peer. Die Zusammenarbeit ist ein wichtiger Meilenstein und eine große Gelegenheit für Seamless, die weitere Türen öffnet – mit entsprechend positiven Auswirkungen auf Umsatz und Ertrag des jungen Technologieunternehmens.

Derzeit sind bei Seamless an allen Fronten Fortschritte bei der Umsetzung der Wachstumsstrategie zu erkennen. Hierbei fährt das Unternehmen weiterhin zweigleisig. Zum einen steht der Ausbau der eigenen Dienstleistungen an, zum anderen schaut man sich nach geeigneten Akquisitionen um, die dem Unternehmen schnell nach vorne helfen sollen. Die Übernahme von GuestWorx von Softnet Technology war solch ein enormer Schritt nach vorne: Damit wurde Seamless in die Lage versetzt, schlüsselfertig komplette WiFi-Lösungen inklusive wichtiger 24/7-Supportdienstleistungen für die Restaurantbranche anzubieten. Die Kundenliste von GuestWorx ist erlesen. Auf ihr stehen unter anderem Holiday Inn, Comfort Inn und Best Western. In mehr als 15 Hotels wurden Systeme installiert. Hinzu kommen insgesamt mehr als 30 Kunden für Supportdienstleistungen. Das erschließt Seamless massives Potenzial für umsatzsteigernde Cross-Selling-Maßnahmen.

Doch mit der Übernahme von GuestWorx ist es nicht genug. Seamless hat die M&A-Profis von Stanton Walker mit einem Mandat beauftragt. Die Consultants sollen für Seamless potenzielle M&A-Targets identifizieren und bewerten sowie im Fall einer Akquisition die Transaktion begleiten. Aus möglichen Akquisitionen sollen steigende Umsätze und exponentielles Wachstum für den WiFi-Netzwerkbereich resultieren. Zusätzliches soll dadurch weiteres Kapital für die Umsetzung des Geschäftsplans von Seamless gesichert werden.

Intern hat man jüngst die Expansionsstrategie mit der Gründung von Alpha Internet Inc. fortgesetzt. Damit begegnet man bei Seamless der Nachfrage von Phenom-Kunden, die keinen eigenen Oracle-Server besitzen bzw. eine entsprechende Infrastruktur aufbauen wollen. Effizienzsteigerung ist ebenfalls ein erklärtes Ziel des Unternehmens, das vor einigen Wochen mit John Domerengo einen neuen President bei der Tochter Seamless Skyy-Fi begrüßen durfte. Mit einer strikten Kostenkontrolle sollen die PS des Unternehmens, die unter anderem aus einer 144%igen Umsatzsteigerung im dritten Quartal 2005 resultieren, auf die Straße gebracht werden. In einer seiner ersten Amtshandlungen hat Domerengo eine Strategie zur Verbesserung der Kosteneffizienz implementiert, die unter anderem die Schließung von 18 Standorten mit schlechten Performances bei gleichzeitiger Eröffnung von 28 effektiveren neuen Standorten beinhaltet. Die neuen Standorte sind konfrom mit den Plänen der Mutter, das Geschäft auszuweiten und gleichzeitig die Profitabilität zu steigern.


Fazit: Die Fortschritte zeigen: Bei Seamless verbessert sich die Geschäftslage an allen Fronten. Von großer Bedeutung ist insbesondere der Deal mit IntentMediaWorks.com, der Signalwirkung für die viel versprechende Phenom-Software hat. Bei unverändert hohem Umsatzwachstum und steigender Profitabilität des Unternehmens sollten stark positive Auswirkungen auf den Aktienkurs nur eine Frage der Zeit sein. Bereits die jüngsten Kursanstiege haben bereits gezeigt, wie schnell der Zug hier nach oben abfahren kann. Die Konsolidierung der Aktie gibt spekulativ orientierten Anlegern nun erneut Gelegenheit, auf einen Turnaround zu setzen und in die Aktie des stark wachsenden Unternehmens einzusteigen. Im Zuge der zunehmenden Zahl guter Nachrichten aus dem Unternehmen sehen wir kurz- bis mittelfristiges Vervielfachungspotenzial für den Aktienkurs.

Seamless WiFi
Frankfurt: WKN A0ERQP
New York: SLWF

Nutzen Sie Ihre Chance und überzeugen Sie sich jetzt selbst von INVEST INSIDE!
Tragen Sie einfach unten Ihre E-Mail Adresse ein und Sie erhalten INVEST INSIDE ab sofort kostenlos für 90 Tage zur Probe.

Nutzen Sie Ihre Chance und handeln Sie jetzt!

[moneyonstreet]

und welcher newsletter entdeckt glif zuerst

nix nur trader, wir brauchen echte longies

[medom]

#1203 money
bin schon seit ein paar tagen drin

[arcoo]

was du hast gekauft

[medom]

logisch

[arcoo]

1201 von moneyonstreet das trif ..ja zum teil auch bei glif ich möchte beton... zum teil hier ist ein biofirma mit super aussichten und mm wollen nur eins die aktien der preis ist nur mittel zum zweck unten werden sie rausgehauen das ist was viele verkert machen und für ein parr hundert $$ verkauf...wenn der preis noch nichts ist!!!! unter 0,15 muß man sie in der hand berhalten und dann muß jeder die entscheidung tref...ob gier oder jemand genug hat das ist jedem selber überlas...aber long das lohnt sich habe viele otc firmen da kann mann nur bis 0,01 gehen und raus nur zock da stimme ich dir zu mit den beitrag arcooaber glif ist vom heuhauf..die nadel wir werden sehen bin long

[arcoo]

man muß das beachten aber wie gesagt schreiben ist das eine aber meistens was dran und hier stimmt es By: hughhefster
07 Jan 2006, 02:37 PM EST
Msg. 2113 of 2115
Jump to msg. #
2006 Uptick through 2006

Glif Long:
Reasons Why-
1) Mission: To improve the diagnostic testing of women’s health by initially increasing the ability to more accurately diagnose cervical cancer and cervical cancer precursors.
2) Short Term Goals

To develop multiple platforms for diagnosing cervical cancer and cervical cancer precursors.

AbReact™
Analyte Specific Reagents (ASR)

To be sold as an adjunct to existing technologies
QuickStrip™
Physician’s Office Test ELISA Tests
Ex-US routine test

Screen the 1.7 billion women who are underserved
3) Additional Technology/Products

Oral Cancer Diagnostic Strip – The Company believes that its test strip can be modified to test for the many oral cancers attributed to HPV. This will be point-of-care product offered to dental professionals.
4) Investment Highlights
Proprietary, patented, antigen based cervical cancer screening test under development using blood and other body fluids
Preliminary experimental results show assay to be substantially more effective than currently available tests
Only blood based product under development for cervical cancer screening
Ongoing US and international regulatory discussions
Experienced management team, board and active advisory board recruited
Additional products in pipeline and in-licensing activity underway
Discussion’s in progress with several acquisition targets
#### you Volumeless trader Dumddiamond Iloseonlymuni I eat you small fries for breakfast.

[arcoo]

BUY-IF


0.0210
-0.0010 -4.55%

Candlestick Analysis
Today’s Candlestick Patterns:

High Wave

[arcoo]

ach so wenn alles gut läuft müßten wir morgen bie 0,03-0,036 zu machen zum ersten mall sehen was meine glaskugel sagt wenn nicht schmeiß ich sie im see

[giesser]

Schmeiss die Kugel in den See

Ich hoffe dass Sie schwer genug ist. Dann nimm die kugel als Gewicht, binde sie dir als Betonklotz an deine Beine und ab mit euch beiden

[arcoo]

gisser mein süßer warum so aufgebracht hat es ein grund bist mein kleiner und bleibst es und tiefer tiefer mit mausi oder bei dir

[arcoo]

machst du auch

[arcoo]

Higher Volume today higher PPS Trend is our friend

Cervical cancer markets Hot stuff in 2006

[arcoo]

gisser way to go dummy another great pick:three for three Bcit nice one loser

[arcoo]

gisser du wirst wünschen auch zu diesen preisen gekauft zu haben --------------------------------------------käuf von freitag------------------------------------------

Time Shares Price
15:58:44 86,500 0.0210
15:52:34 500 0.0230
15:46:40 5,000 0.0210
15:40:08 91,000 0.0220
15:40:08 20,000 0.0230
15:40:03 9,000 0.0235
15:32:53 13,000 0.0240
15:25:38 13,000 0.0235
15:22:36 87,000 0.0235
15:22:04 21,000 0.0235
15:15:17 20,000 0.0230
15:15:13 35,100 0.0230
15:14:50 40,000 0.0230
15:14:48 5,000 0.0230
15:02:42 46,000 0.0230
15:00:18 40,000 0.0230
14:59:48 50,000 0.0220
14:58:26 20,000 0.0225
14:57:29 100,000 0.0230
14:47:39 8,700 0.0230
14:44:29 120,000 0.0230
14:39:13 5,000 0.0230
14:38:28 19,000 0.0234
14:36:30 85,000 0.0230
14:34:38 190,000 0.0230
14:33:00 45,000 0.0220
14:30:36 5,000 0.0230
14:30:10 8,000 0.0230
14:30:09 100,000 0.0230
14:30:08 100,000 0.0231
14:27:41 5,000 0.0240
14:27:38 14,000 0.0240
14:26:52 5,000 0.0240
14:26:00 20,000 0.0240
14:25:40 15,000 0.0240
14:24:23 5,000 0.0240
14:21:12 26,000 0.0240
14:18:15 55,000 0.0240
14:18:05 5,000 0.0240
14:17:45 50,000 0.0240
14:17:24 25,000 0.0240
14:16:06 5,000 0.0240
14:01:42 100 0.0250
13:59:53 10,000 0.0250
13:59:53 10,000 0.0249
13:53:34 195,000 0.0240
13:53:22 100,000 0.0250
13:52:58 3,800 0.0260
13:52:56 3,800 0.0250
13:52:06 5,000 0.0250
13:50:36 9,000 0.0250
13:50:14 50,000 0.0250
13:47:26 195,000 0.0259
13:46:11 10,000 0.0250
13:46:08 50,000 0.0250
13:45:57 5,000 0.0260
13:45:49 15,000 0.0250
13:45:34 5,000 0.0250
13:44:29 1,000 0.0250
13:44:28 105,500 0.0250
13:43:49 19,000 0.0250
13:43:47 19,000 0.0260
13:42:06 50,000 0.0260
13:41:59 10,000 0.0250
13:41:33 75,000 0.0250
13:41:31 5,000 0.0250
13:41:09 40,000 0.0250
13:40:59 5,000 0.0250
13:40:38 25,000 0.0250
13:40:15 15,000 0.0240
13:40:00 50,000 0.0240
13:39:50 50,000 0.0240
13:39:15 5,000 0.0240
13:38:27 10,000 0.0230
13:38:16 13,070 0.0230
13:38:03 5,000 0.0230
13:36:49 56,500 0.0230
13:36:49 50,000 0.0230
13:26:28 5,000 0.0230
13:26:18 5,000 0.0230
13:25:09 93,500 0.0230
13:18:53 5,100 0.0220
13:10:10 6,500 0.0220
13:10:10 50,000 0.0220
13:10:10 4,100 0.0220
13:10:04 600 0.0210
13:09:21 113,500 0.0220
12:56:46 100,000 0.0220
12:55:16 83,000 0.0217
12:55:11 100,000 0.0217
12:55:09 5,000 0.0217
12:46:03 50,000 0.0217
12:45:16 50,000 0.0217
12:37:45 200,000 0.0210
12:35:54 300,000 0.0210
12:34:34 28,000 0.0210
12:27:41 50,000 0.0210
12:18:40 22,702 0.0210
12:18:29 10,000 0.0210
12:10:58 100,000 0.0210
12:09:00 30,000 0.0210
11:58:51 50,000 0.0210
11:30:19 50,000 0.0209
11:30:19 100,000 0.0210
11:27:08 42,000 0.0210
10:57:06 16,900 0.0200
10:57:01 50,000 0.0200
10:55:59 5,000 0.0200
10:53:20 28,100 0.0200
10:51:52 10,500 0.0200
10:51:36 5,000 0.0200
10:46:05 50,000 0.0195
10:44:29 50,000 0.0195
10:43:53 100,000 0.0195
10:41:32 50,000 0.0195
10:39:43 18,500 0.0195
10:39:38 45,000 0.0195
10:39:37 5,000 0.0195
10:38:56 5,000 0.0195
10:35:48 20,000 0.0195
10:04:41 5,000 0.0201
09:59:29 37,600 0.0200
09:57:51 50,000 0.0200
09:57:48 40,000 0.0200
09:55:08 10,000 0.0200
09:53:57 30,000 0.0205
09:53:50 30,000 0.0220
09:38:02 40,000 0.0220
09:38:01 40,000 0.0219
09:30:13 3,000 0.0220
09:30:09 5,000 0.0220

[arcoo]

Is this potential ONE DOLLAR -- comments appreciated -- or, other potential more feasible -- Thanks --

[ket1390]

Gliffin party kommt ins Rollen. Wenn wir die 0.026 Resistence durchbrechen dann...

[arcoo]

Grant Life Sciences To Exhibit At WealthExpo January 12-14 In Houston

Monday , January 09, 2006 00:07 ET

(financialwire.net via COMTEX) -- January 9, 2006 (FinancialWire) Grant Life Sciences (OTCBB: GLIF) will exhibit at the WealthExpo (http://www.worldforumexpo.com), an Investrend Forums (http://www.investrendforums.com) "SELECT" event, in Houston, Texas, on January 12-14 at the Westin Galleria Hotel.

Past participants have included Generex Biotech (NASDAQ: GNBT), and a presenter is expected to be Frank Holmes, CEO of US Global Investors (NASDAQ: GROW). Texas is home to several well-known public companies, such as Exxon Mobil (NYSE: XOM). Houston also boasts a high net worth investor base.

"Houston is the nation`s fourth largest city," noted Mike Loebel, principal in Worldwide Forums of Scottsdale, the producer of the WealthExpos. "Its citizens deserve to be in the mainstream of investing opportunities on Wall Street and elsewhere, and that`s exactly what WealthExpo delivers."

Those who register in advance may attend free; attendees otherwise will be charged $35 at the door. Workshops are scheduled in Energy, Commodities, Mutual Funds and Stock Trading. It also showcases new software, brokerage, advisory and research firms.

Speakers include Walter Bressert, John Person, Jake Bernstein and Robin Dain. Educators Vince Rowe and Dr. Barry Burns will also speak.

Stock experts Neil George and Elliot Gue will speak, and investing insight will be provided by Dan Gramza, Don Bright, Afshin Taghechian and Joe Cussisk.

The Houston event is scheduled 1 p.m. to 7 p.m. on Thursday, 8:30 a.m. to 5 p.m. on Friday and 8:30 a.m. to 4 p.m. on Saturday.

WealthExpos are also scheduled March 16-18 in Anaheim, May 4-6 in Atlanta, and September 7-9 in Dallas.

Public companies wanting information about exhibiting should click on http://www.investrend.com/contact.asp to be assure of all the special, enhanced visibility programs associated with becoming an Investrend "SELECT" participant in a "SELECT" event.

Grant Life Sciences, Inc., a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for detecting disease with emphasis on the detection of cervical disease. The company is developing two cervical cancer tests, Enzyme Linked Immunosorbent Assay Test (ELISA), to be run in a laboratory, and a rapid test to be a point-of-care test that would be administered in the hospital, physician`s office, clinic, or at home or in outdoor settings. Its tests would detect the presence or absence of specific antibodies that are produced only if cancer-causing HPV is present in the body and consequent oncogenic or cancer-promoting changes occur. The company also holds worldwide rights to diagnostic devices for HIV-1, HIV-2, and dengue fever, and proprietary colloidal gold reagent, an ingredient used by manufacturers of rapid tests as a detectable label. Grant Life Sciences was organized in 1998 and is based in Murray, Utah.

Generex Biotech Corp. had enrolled in Investrend Research`s unique and pioneering professional analyst program, which facilitates independent analysts to provide financial coverage for shareholders and investors in companies that otherwise would have little or no analyst following. Enrollment in standards-based research is an important measure of a company`s commitment to transparency and Good Governance.

In a Focus Report initiated by Investrend Research analyst Shailesh Dhuri, the analyst stated on June 6, 2005, that the company "is working towards creating a potentially winning technology, with strong feature improvements over current options in the market."

The company`s research is now stale.

The Investrend Research program is the largest in the world and includes a number of safeguards to reduce or eliminate conflict. These systems, including media coverage and endorsements, may be accessed at http://www.investrendresearch.com

Investrend Research subscribes to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com, and adheres to the Guidelines for independent providers jointly endorsed by the National Investor Relations Institute (http://www.niri.org) and the CFA Institute (http://www.cfainstitute.org).

Buyside Magazine has stated that Investrend Research "remains in the vanguard of both standards and independence." ODwyerPR has cited Investrend Research as "exceeding the standards of CFAI-NIRI." The CFA Magazine, citing Investrend and its affiliates as having "strict rules about compensation and full disclosure," which "should go a long way towards ensuring objectivity," said "issuer-paid research is here to stay." Investrend has been cited by the Dow Jones Newswires, Financial Mail, Shareholder Value, and NIRI`s "IR Update," which stated that Investrend "accomplishes the goal and more." Investrend`s model has been endorsed by the New York Times, former SEC Chair Arthur Levitt and shareholders themselves, 70.9% of whom said in a survey at InvestoPedia, that a company that enrolls for "legitimate fee-based research is making a positive statement about its investment potential." A survey at Charles Schwab & Co. revealed that 78% of active shareholders now "value research from independent firms over analysts by Wall Street firms with financial ties to the companies they are rating."

Enrollment fees for the Focus research platform are $9,950. The fees were paid by Investor Relations International.

All independent sponsored research distributed by Investrend Research Syndicate are enrolled for investor-monitoring by the Shareholders Research Alliance at http://www.shareholdersresearch.com.

Complete information about any company enrolled in an Investrend shareholder empowerment platform, including those of its affiliates and independent analysts and webcasters, including disclosures and disclaimers, is available at the company`s InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes and on each report and press release, and investors are advised to read those disclosures carefully before trading in the equities of any enrolled company.

For up-to-the-minute news, features and links click on http://www.financialwire.net.

FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp.

For a free annual report on a company mentioned in the news, please click on http://investrend.ar.wilink.com/?level=279.

The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268.

http://www.financialwire.net

(C) 2006 financialwire.net, Inc. All rights reserved.

[fs2003]

1$..........

[jaxn]

[posting]19.616.477 von fs2003 am 09.01.06 13:15:17[/posting]aber zuerst zu 0,016.
gap close.
leider

[arcoo]

oder die 0,026 close und wir springen

[arcoo]

Congress Must Reduce Disparities in Domestic HIV/AIDS Program
E-mail or Print this story

10 January 2006, 08:49am ET

National Campaign Will Urge Congress to Address Inequalities
in the Ryan White CARE Act
WASHINGTON, Jan. 10 /PRNewswire/ -- The National Minority Health Month Foundation (NMHMF) today announces a broad-based national campaign aimed at encouraging the U.S. Congress to support the reauthorization and modernization of the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act in 2006.

Recent patterns in the United States show that HIV/AIDS increasingly affects African Americans, Latinos, and other racial and ethnic minorities. In 2004, minorities accounted for almost three-fourths of new cases of AIDS in an HIV/AIDS surveillance report by the Centers for Disease Control and Prevention (CDC). Of these newly identified AIDS patients, 48 percent were African Americans and 21 percent were Latinos. The rate also continued to rise among women, who accounted for 27 percent of new AIDS cases in 2004. Of these women newly diagnosed with AIDS, 67 percent were African Americans and 15 percent were Latinas.

"The Ryan White Act is a critically important program in the prevention and treatment of HIV/AIDS in the United States," said NMHMF Executive Director Gary A. Puckrein, PhD. "Our national campaign will focus on encouraging HIV- positive patients and community leaders across the country to urge Congress to address the inequalities of the Ryan White CARE Act."

These inequalities are vast. The CARE Act`s current focus on legacy communities -- many of which are large, densely populated centers, such as New York City -- leaves gaps in prevention and treatment efforts in Alabama, Florida, Georgia, and elsewhere in the country, where incidence and prevalence of HIV/AIDS are increasing among minority and non minority populations.

"Antiretroviral drugs did not exist when the CARE Act was drafted. We must modernize our HIV/AIDS program both to reflect the changing demographics of this epidemic and to ensure that everyone receives the most advanced treatment and medical care available," said Dr. Puckrein.

About the National Minority Health Month Foundation

Founded as a nonprofit organization in 1998, the National Minority Health Month Foundation was established to strengthen national and local efforts to eliminate the disproportionate burden of premature death and preventable illness in racial and ethnic minorities and other special populations through the use of evidence-based, data-driven initiatives. The Foundation has developed a comprehensive relational data platform for identifying the prevalence of health-status and health-care disparities at the zip-code level. This centralized data warehouse allows the Foundation to house vital statistics; demographic, environmental, claims, prescription-drug, and clinical-laboratory values; health-care access points, and other data. The Foundation is thus able to measure and forecast health status in small geographic areas, evaluate the impact of specific interventions, monitor changes in health outcomes, and serve as a valuable resource for the health- disparities movement.

For additional information and interview requests, please contact Cleve Mesidor at [phone].


(Voluntary Disclosure: LT Rating- Buy)

[moneyonstreet]

next step of GLIF-presentation.. see here

http://archconferences.com/

[moneyonstreet]

seven companies... one of them ist glif ... another one is nnan... zu nnan a little bit info

financials
http://finance.yahoo.com/q/is?s=nnan.ob

marktet-cap 114 mio. euronen


just waiting... glif-market-cap round about 2 million usd

[arcoo]

auch mit bei

10 Jan 2006, 03:44pm ET

Last price:3.12 ---
(Unchanged)
YAKC detailed pricing and financial information. Metric Value
Bid: 2.96
Ask: 4.89
Day`s Low & High: 3.05 - 3.14
Open: 3.08
Previous Close: 3.12
Volume: 46,090
Avg. Volume: 55,079
Market Capitalization: 40.24 M ------
52-week range: 2.90 to 8.50
1 week change: 1.03%
1 month change: 9.03%
1 year change: 50.39%
P/E: 13.16

[arcoo]

Mentioned Last Change
NVD 1.43 0.11dollars or (8.33%)
BIPH 1.94 0.15dollars or (8.37%)
CBAI 0.20 (Unchanged)
GLIF 0.021 (Unchanged)
NNAN 2.19 (Unchanged)
YAKC 3.12 (Unchanged)
NEW YORK--(BUSINESS WIRE)--Jan. 9, 2006--Arch Investment Conferences, Inc., www.archconferences.com is proud to announce its conference series for the first 3 months of 2006 beginning Thursday January 19, 2006, 7:30 to 2:00PM, in New York at the Hotel Plaza Athenee, 37 East 64th Street, New York

[moneyonstreet]

aus amiland... investor-voice:


There definately is information on the horizon as GLIF are exhibiting at the WeathExpo forum Jan 12 - 14 in Houston, Texas, which is co-incidentally not even 5 minutes from my office...! I am registered and will attend on Thursday and give you guys feedback Thursday evening. I wanted info and now I get a three day audience with the company.


waiting for information...

[arcoo]

mony wo ist das bord bei mir im briefkasten bitte danke

[arcoo]

By:
10 Jan 2006, 06:37 PM EST
Msg. 2143 of 2143
Jump to msg. #
12-14.01.2006 texas http://www.knobias.com/individual/public/news.htm?eid=3.1.4f… Conference to Be Held January 19, 2006, at the Hotel Plaza Athenee in New York

(Voluntary Disclosure: LT Rating- Strong Buy)

[moneyonstreet]

schaut... schaut ihr bergsteiger, nach kräftiger rutschbahn schöne drei gipfel bestiegen aber auch wieder in das tal herab gestiegen ;aber die täler sind nicht mehr so tief . die frage ist, wie hoch ist der nächste gipfel, vielleicht ein zehntausender mit gaaaaaaanz laaaaaaaaaangem aufstieg . we will see

[moneyonstreet]

2006 will be glif-year

mark this post ... i say market-cap min. 50 mill. usd is no problem on the long side after succssfull FDA-regulation (no guarantee)... perhaps over 100 mill. usd with lucky punch... again: whats o/s by the time. GLIF is coming

0,1
0,5
1,0 arcoo long

[moneyonstreet]

arca...

http://www.arca-ex.com/inside/


hier traden die profis... otcbb-trading for schlappe 15 k p.a.

[arcoo]

mall sehen was rauskom.... Grant Life, Cord Blood, Novadel To Exhibit At WealthExpo January 12-14 In Houston

[Boersenolly]

[posting]19.665.139 von moneyonstreet am 11.01.06 22:35:16[/posting]Hallo Money,

von mir aus können wir einen zehntausender besteigen, ich bin bereit und gut gerüstet , je eher daran je eher da droben, hoffentlich kommt kein starker Nebel der uns den Aufstieg erschwert, und dann kurz vorm Gipfel vom Hubschrauber abholen lassen , das wir uns den lästigen Abstieg/Abrutsch ersparen.
Ich hoffe das ist unser weg in der nahen Zukunft.

In diesem Sinne Guten Aufstieg BO

[arcoo]

schön abend und hop---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Press Release Source: Digene Corporation


German Insurer First to Implement Routine HPV Testing for Cervical Cancer Screening in Europe
Thursday January 12, 7:00 am ET
- Protocol Requires Use of the Digene(R) HPV Test -


GAITHERSBURG, Md., Jan. 12 /PRNewswire-FirstCall/ -- Europe`s first cervical cancer screening program using routine HPV testing will be implemented by Deutsche BKK, a major public-health insurance provider in central Germany, in partnership with the local gynecologists` association and a regional hospital, announced Digene Corporation (Nasdaq: DIGE - News). The protocol adopted by BKK requires use of The Digene® HPV Test, also marketed as the DNAwithPap® Test. It is the only FDA-approved test for high-risk types of the human papillomavirus (HPV), which cause virtually all cases of cervical cancer. The test is approved in the United States for use along with the Pap to screen women age 30 and older, the group most at risk of developing cervical cancer.
ADVERTISEMENT


"This announcement in Germany is an important milestone for cervical cancer screening and prevention programs globally, and will trigger the attention of other countries in Europe with similar public healthcare systems as a new standard of care," said Xavier Bosch, MD, Chief of the Epidemiology and Cancer Registration Unit for the Catalan Institute of Oncology in Spain. "Implementation of HPV DNA testing for routine screening introduces on a large scale the next-generation technology for cervical cancer screening, which has proven to offer significant advantages for the early detection of cervical cancer and its precursor conditions around the world."

Under the new protocol of Deutsche BKK, which serves the Wolfsburg region of Germany (home of Volkswagen), all women age 30 and older will be tested for high-risk HPV along with the Pap. Women who have HPV and an abnormal Pap will be referred for an immediate colposcopy. Those who have HPV but a normal Pap will be re-tested in 9-12 months, unless they choose to go right to colposcopy due to anxiety. Women who do not have HPV but an abnormal Pap will be re- tested as well.

"The Wolfsburg integration of routine HPV testing into a disease- management approach should have a ripple effect over time throughout the rest of Germany, Europe as a whole and even in other parts of the world, such as Latin America and the Asia-Pacific, where they have similar healthcare systems," said Evan Jones, Digene`s Chairman and Chief Executive Officer. "Cost-effectiveness is critical for publicly funded health programs, and it is increasingly recognized that HPV testing can significantly increase the ability to prevent the morbidity and mortality associated with cervical cancer, while focusing scarce healthcare resources on women most at risk."



Go Glif

[arcoo]

Press Release Source: Digene Corporation


German Insurer First to Implement Routine HPV Testing for Cervical Cancer Screening in Europe
Thursday January 12, 7:00 am ET
- Protocol Requires Use of the Digene(R) HPV Test -


GAITHERSBURG, Md., Jan. 12 /PRNewswire-FirstCall/ -- Europe`s first cervical cancer screening program using routine HPV testing will be implemented by Deutsche BKK, a major public-health insurance provider in central Germany, in partnership with the local gynecologists` association and a regional hospital, announced Digene Corporation (Nasdaq: DIGE - News). The protocol adopted by BKK requires use of The Digene® HPV Test, also marketed as the DNAwithPap® Test. It is the only FDA-approved test for high-risk types of the human papillomavirus (HPV), which cause virtually all cases of cervical cancer. The test is approved in the United States for use along with the Pap to screen women age 30 and older, the group most at risk of developing cervical cancer.
ADVERTISEMENT


"This announcement in Germany is an important milestone for cervical cancer screening and prevention programs globally, and will trigger the attention of other countries in Europe with similar public healthcare systems as a new standard of care," said Xavier Bosch, MD, Chief of the Epidemiology and Cancer Registration Unit for the Catalan Institute of Oncology in Spain. "Implementation of HPV DNA testing for routine screening introduces on a large scale the next-generation technology for cervical cancer screening, which has proven to offer significant advantages for the early detection of cervical cancer and its precursor conditions around the world."

Under the new protocol of Deutsche BKK, which serves the Wolfsburg region of Germany (home of Volkswagen), all women age 30 and older will be tested for high-risk HPV along with the Pap. Women who have HPV and an abnormal Pap will be referred for an immediate colposcopy. Those who have HPV but a normal Pap will be re-tested in 9-12 months, unless they choose to go right to colposcopy due to anxiety. Women who do not have HPV but an abnormal Pap will be re- tested as well.

"The Wolfsburg integration of routine HPV testing into a disease- management approach should have a ripple effect over time throughout the rest of Germany, Europe as a whole and even in other parts of the world, such as Latin America and the Asia-Pacific, where they have similar healthcare systems," said Evan Jones, Digene`s Chairman and Chief Executive Officer. "Cost-effectiveness is critical for publicly funded health programs, and it is increasingly recognized that HPV testing can significantly increase the ability to prevent the morbidity and mortality associated with cervical cancer, while focusing scarce healthcare resources on women most at risk."



Go Glif

[arcoo]

STAY IN THE GAME! MEMORABLE QUOTES

"You Want details? Fine. I drive a Ferrari, 355 Cabriolet, What`s up? I have a ridiculous house in the South Fork. I have every toy you could possibly imagine. And best of all kids,I am liquid."

"I`m talking about liquid. Rich enough to have your own jet. Rich enough not to waste time. Fifty, a hundred million dollars, buddy. A player. Or nothing." -Gordon Gekko

"The richest one percent of this country owns half our country`s wealth, five trillion dollars. One third of that comes from hard work, two thirds comes from inheritance, interest on interest accumulating to widows and idiot sons and what I do, stock and real estate speculation. It`s bullshit. You got ninety percent of the American public out there with little or no net worth. I create nothing. I own."- Gordon Gekko

"It`s not a question of enough, pal. It`s a zero sum game, somebody wins, somebody loses. Money itself isn`t lost or made, it`s simply transferred from one perception to another."-Gordon
Gekko

"And there is no such thing as a no sale call. A sale is made on every call you make. Either you sell the client some stock or he sells you a reason he can`t. Either way a sale is made, the only question is who is gonna close? You or him? Now be relentless, that`s it, I`m done."
GLIF (bottom)

[moneyonstreet]

[posting]19.684.435 von Boersenolly am 12.01.06 22:01:56[/posting]that`s what you need

- blow the fog away when it`s coming



- good condition for climbing



- the right tool for sos-situation

[moneyonstreet]

- und jetzt hat rsi richtig plumps gemacht

- this week great support building on 0,02

- otherwise great resistance on 0,03

- look at level II where we can go.. soonly

[moneyonstreet]

seems to be time of accumlation for next run...

[moneyonstreet]

resistance bröselt dahin... support (built this week!!!!) is coming... 0,1 is coming

Support/Resistance
Type Value Conf.
resist. 0.28 2
resist. 0.17 2
resist. 0.14 6
resist. 0.13 11
resist. 0.10 2
resist. 0.08 2
resist. 0.06 2
resist. 0.04 4
resist. 0.03 21
supp 0.02 24
supp 0.01 2

[arcoo]

GLIF.021x.023.Has Sachen going.1)Read fettes below.That eines Paares funkt vermutlich Kaufen in der folgenden Woche. Auch Bewachung für folgenden Pfosten für Nr. 2) event.Got innen heute, nachdem an irgendein DD warum dieses RU-Mitkaufen getan worden ist. Dann erhielt ich innen am 023, nachdem ich mein DD getan hatte. (COMTEX) B: GrantcLeben, NetzkabelcBlut, Bei WealthExpo Janua Auszustellendes Novadel B: Grantleben, Netzkabelblut, bei WealthExpo Januar auszustellendes Novadel 12-14 in Hou Jan. 11, 2006 (financialwire.net über COMTEX) -- Januar 11, 2006 (FinancialWire) Grantlebenwissenschaften (OTCBB: GLIF), NetzkabelcBlut Amerika (OTCBB: CBAI) und Novadel Pharma (Amex: NVD) stellt beim WealthExpo (http://www.worldforumexpo.com), Foren eines Investrend (http://www.investrendforums.com)"VORWÄHLEN" Fall, in Houston, Texas, an Januar 12-14 im Hotel Westin Galleria aus. Ein Vorführer wird erwartet, aufrichtiges Holmes, CEO zu sein der globalen Investoren US (Nasdaq: WACHSEN Sie). "Houston ist die 4. größte Stadt der Nation," notiertes Mikrophon Loebel, das in den weltweiten Foren von Scottsdale, der Produzent des WealthExpos hauptsächlich ist. "seine Bürger verdienen, im Mainstream der Investierung von Gelegenheiten auf Wall Street zu sein und anderwohin, und das ist genau, was WealthExpo liefert.", Die, die im voraus registrieren, können frei beachten; Teilnehmer anders werden $35 an der Tür aufgeladen. Werkstätten werden in der Energie, in den Gebrauchsgütern, in den Investmentfonds und im Aktienhandel festgelegt. Sie stellt auch neue beratender und der Forschung Unternehmen der Software, der Maklertätigkeit, zur Schau. Lautsprecher schließen Walter Bressert, Johnperson, Jake Bernstein und Robin Dain mit ein. Erzieher Vince Rowe und Dr. Barry Burns sprechen auch. Auf lagerexperten Neil George und Elliot Gue sprechen, und die Investierung des Einblickes wird von Dan Gramza zur Verfügung gestellt, helles, Afshin Taghechian und Joe Cussisk anzieht. Dem Houstonfall wird 1 P.M. bis 7 P.M. am Donnerstag, 8:30 a.m. bis 5 P.M. am Freitag und 8:30 a.m. bis 4 P.M. am Samstag festgelegt. WealthExpos werden auch März 16-18 in Anaheim, Mai 4-6 in Atlanta und September 7-9 in Dallas festgelegt. Die Aktiengesellschaften, die Informationen über das Ausstellen wünschen, sollten http://www.investrend.com/contact.asp an klicken, um zu sein versichern von allen speziellen, erhöhten Sichtprogrammen, die mit dem Werden ein Investrend dazugehörig sind, ", das AUSERWÄHLTER "Teilnehmer an Fall" VORWÄHLEN ". Grant Life Sciences, Inc., eine Entwicklungsstadiumsfirma, engagiert sich in der Forschung, in der Entwicklung, im Marketing und im Verkauf der Diagnoseinstallationssätze für das Ermitteln von Krankheit mit Betonung auf der Abfragung der zervikalen Krankheit. Die Firma entwickelt zwei zervikale Krebstests, Enzym verbundenen Immunosorbentprobentest (ELISA), in des Arztes, Klinik oder zu Hause oder in im Freieneinstellungen gelaufen zu werden ein Labor und ein schneller Test, um ein Punkt-von-Obachttest zu sein, der ausgeübt würde im Krankenhaus, Büro. Seine Tests würden das Vorhandensein oder Fehlen spezifischen Antikörpern ermitteln, die produziert werden nur wenn, HPV Krebs-verursachend, ist anwesend im Körper und konsequente onkogenische oder Krebs-fördernänderungen eintreten. Die Firma hält auch weltweite Rechte zu den Diagnosevorrichtungen für Hiv-1, Hiv-2 und Dandyfieberfieber und eigenes kolloidales Goldreagens, ein Bestandteil, der durch Hersteller der schnellen Tests als nachweisbarer Aufkleber benutzt wird. Grantlebenwissenschaften wurden 1998 organisiert und basieren in Murray, Utah. Grant Life Sciences, Inc., eine Entwicklungsstadiumsfirma, engagiert sich in der Forschung, in der Entwicklung, im Marketing und im Verkauf der Diagnoseinstallationssätze für das Ermitteln von Krankheit mit Betonung auf der Abfragung der zervikalen Krankheit. Die Firma entwickelt zwei zervikale Krebstests, den Enzym verbundenen in ein Labor und einen schnellen Test, um ein Punkt-von-Obachttest zu sein zu laufenden Immunosorbentprobentest (ELISA), der im Krankenhaus, Büro des Arztes, Klinik oder zu Hause ausgeübt würde oder in im Freieneinstellungen. Seine Tests würden die Anwesenheit ermitteln, oder Fehlen spezifische Antikörper, die produziert werden, nur wenn, HPV Krebs-zu verursachen im Körper anwesend ist, und konsequente onkogenische oder Krebs-fördernänderungen treten auf. Die Firma hält auch weltweite Rechte zu den Diagnosevorrichtungen für Hiv-1, Hiv-2 und Dandyfieberfieber und eigenes kolloidales Goldreagens, ein Bestandteil, der durch Hersteller der schnellen Tests als nachweisbarer Aufkleber benutzt wird. Grantlebenwissenschaften wurden 1998 organisiert und basieren in Murray, Utah. Mission Netzkabelblut-Amerikas ist, die respektierte Stammzelle-Bewahrungfirma in der Welt zu sein. Netzkabelblut Amerika erzielt seine Mission durch das Erziehen der erwartungsvollen Eltern, der Familien mit einer Geschichte der Krankheit, der kritisch kranken Patienten und aller anderer, die über diese Lebeneinsparunggelegenheit erlernen möchten. Wir stellen konstante Obacht und Unterstützung zu den Familien zur Verfügung deren Stammzellen wir und zu den medizinischen Fachleuten konservieren, die ihnen helfen, so zu tun. Wir werden den Kampf zu bedrohender Krankheit des Kampflebens angeschlossen, indem man auf einmal eine Person erzieht. Gegründet an Sommer 2002 und funktionsfähiges an Januar 1, 2003, Netzkabelpartner, eine Netzkabelblut-Amerikafirma, hat sich als nationaler Standardkonkurrent des Platins in der Nabelnetzkabel-Blutspeicherindustrie hergestellt. Netzkabelpartner wurden durch Matthew L. Schissler, Vorsitzender und CEO, Stephanie Schissler, Präsident u. COO und Laura Fitzpatrick, Vizepräsident der strategischen Relationen gegründet. Von Cord Blood America, Inc. ist einer öffentlich gehandelten Firma, geregelt die Vereinigten Staat Aktien u. Austauschkommission. Unsere Stammaktien handeln auf dem Anschlagbrett Nasdaq OTC, unter dem Symbol: CBAI. Netzkabelpartner wurden auf einer einfachen Grundregel gegründet: Die Familien, die Stammzellebewahrung suchen, sollten arbeiten nie müssen, um dieses zu erzielen. Indem wir solche Services wie medizinische Installationssatzvorbereitung, medizinische Eilboteanordnung, 24/7 Kundendienst, einfache Einschreibung und ein Preis für alle Dienstleistungen zusammenrollen, glauben wir einer unvergleichlichn Verpflichtung zu unseren Klienten, und sind die Grundlage für das Zur Verfügung stellen der höchste vorhandenen Qualitätsstammzellebewahrung. Novadel Pharma, Inc. entwickelt die Anwendungsdroge-Anlieferungssysteme für Verordnung, im Freiverkehr gehandelt und Veterinärdrogen. Sein Mundanlieferungssystem ist ein sprachlicher Spray und ermöglicht Drogeabsorption durch das Mundmucosa und in den Blutstrom. Die Firma konzentriert auf die Entwicklung von sechs Produkten, einschließlich des Nitroglyzerins, sumatriptan, alprazolam, des zolpidem, des ondansetron und des propofol. Sie entwickelt auch die vielen Produkte und enthält clemastine, loratadine und sprachliche Sprays des estradiol und des Progesterons. Die Firma hat Lizenzvereinbarungen mit Manhattan Pharmaceuticals, Inc., Velcera Pharmaceuticals, Inc., Par Pharmaceutical, Inc., INyX USA, Ltd., und Hana Biosciences, Inc. seine Betriebe sind in den Vereinigten Staaten, im Kanada und im europäischen Anschluß. Die Firma wurde durch Harry A gegründet. Dugger. Es wurde früher bekannt wie Pharmaconsult und seinem Namen zu Flemington Pharmaceutical Corporation 1991 und zu NovaDel Pharma, Inc. 2002 geändert. Novadel Pharma basiert in Flemington, neues Jersey. Für up-to-the-minute Nachrichten klicken Eigenschaften und Verbindungen an http://www.financialwire.net. FinancialWire ist ein unabhängiger, eigener Informationsdienst der Informationen Investrend, eine Abteilung der Kommunikationen Investrend, Inc.. Für es ist nicht einen Pressekommuniqué Service und empfängt keinen Ausgleich seine Nachrichten oder Meinungen. Andere Abteilungen von Investrend liefern jedoch Aktionärempowermentplattformen wie Foren, unabhängige Forschung und Webcasting. Zu mehr Information oder die tägliche Zusammenfassung FirstAlert der Nachrichten zu empfangen, klicken Kommentar, Forschungsreports, webcasts, Fälle und Konferenzanrufe, an http://www.investrend.com/contact.asp. Für einen freien jährlichen Bericht über eine Firma, die in den Nachrichten erwähnt wird, klicken Sie bitte an http://investrend.ar.wilink.com/?level=279. Der NewsFeed FinancialWire ist jetzt in den mehrfachen Formaten für Ihren Aufstellungsort oder der Schreibtisch vorhanden, frei. Klicken Sie an: http://www.investrend.com/XmlFeeds?level=268. http://www.financialwire.net (c) 2006 financialwire.net, Inc. alle Rechte vorbehalten.

[fs2003]

German Insurer First to Implement Routine HPV Testing for Cervical Cancer Screening in Europe
Thursday January 12, 7:00 am ET
- Protocol Requires Use of the Digene(R) HPV Test -


GAITHERSBURG, Md., Jan. 12 /PRNewswire-FirstCall/ -- Europe`s first cervical cancer screening program using routine HPV testing will be implemented by Deutsche BKK, a major public-health insurance provider in central Germany, in partnership with the local gynecologists` association and a regional hospital, announced Digene Corporation (Nasdaq: DIGE - News). The protocol adopted by BKK requires use of The Digene® HPV Test, also marketed as the DNAwithPap® Test. It is the only FDA-approved test for high-risk types of the human papillomavirus (HPV), which cause virtually all cases of cervical cancer. The test is approved in the United States for use along with the Pap to screen women age 30 and older, the group most at risk of developing cervical cancer.
ADVERTISEMENT


"This announcement in Germany is an important milestone for cervical cancer screening and prevention programs globally, and will trigger the attention of other countries in Europe with similar public healthcare systems as a new standard of care," said Xavier Bosch, MD, Chief of the Epidemiology and Cancer Registration Unit for the Catalan Institute of Oncology in Spain. "Implementation of HPV DNA testing for routine screening introduces on a large scale the next-generation technology for cervical cancer screening, which has proven to offer significant advantages for the early detection of cervical cancer and its precursor conditions around the world."

Under the new protocol of Deutsche BKK, which serves the Wolfsburg region of Germany (home of Volkswagen), all women age 30 and older will be tested for high-risk HPV along with the Pap. Women who have HPV and an abnormal Pap will be referred for an immediate colposcopy. Those who have HPV but a normal Pap will be re-tested in 9-12 months, unless they choose to go right to colposcopy due to anxiety. Women who do not have HPV but an abnormal Pap will be re- tested as well.

"The Wolfsburg integration of routine HPV testing into a disease- management approach should have a ripple effect over time throughout the rest of Germany, Europe as a whole and even in other parts of the world, such as Latin America and the Asia-Pacific, where they have similar healthcare systems," said Evan Jones, Digene`s Chairman and Chief Executive Officer. "Cost-effectiveness is critical for publicly funded health programs, and it is increasingly recognized that HPV testing can significantly increase the ability to prevent the morbidity and mortality associated with cervical cancer, while focusing scarce healthcare resources on women most at risk."

[arcoo]

KÖNIGEN DER OTC schön abend noch bis montag

[arcoo]

ach ja unsere großen an der otc alle bei level 2 buy NITE 50 0.021
12:02 Close
Tradition Asiel Securities Inc.

NASDAQ
212-791-4770

OTCBB
212-791-5335
TASL 50 0.0205 ↑
08:51 Close
Track ECN

MAIN
888-287-8832

TRADING DESK
718-923-3177
TRAC 50 0.02 ↑
09:32 Close
Archipelago Trading Services, Inc.

NASDAQ TRADING
312-969-1318

OTCBB TRADING
312-442-7700
ARCA 50 0.02
13:25 Close
UBS Securities LLC

TRADING DEPARTMENT
203-719-7400
UBSS

[fs2003]

[arcoo]

GLIF.021- und PLNI.006.True-Löwen I hoffen folgende Woche Januar 19., verkündet Bogen die Bogenkonferenz-Reihe für Klein-Kappe und Mikrobogen verkündet die Bogenkonferenz-Reihe für Klein-Kappen- und Mikro-Kappenfirmengeschäftsherausgeber NEUES YORK -- (business WIRE) -- Jan.. 9, 2006 -- Arch Investment Conferences, Inc., www.archconferences.com ist stolz, seine Konferenz-Reihe für die ersten 3 Monate von 2006 anfangendonnerstag Januar 19, 2006, 7:30 bis 2:00PM, in neuem York an der Hotelplaza Athenee, 37 Ost64th Straße, New York City zu verkünden. Tobin Smith der Forschung ChangeWave u. FOXNEWS-Mitwirkender, Charles Payne der Wall Street Strategien u. DES FOXNEWS-Mitwirkenden und Peter Leeds von PeterLeeds.com sind die gekennzeichneten Gastteilnehmer, denen Firmen sich darstellen werden. Das Firmendarstellen sind: Netzkabelblutamerikas NaturalNano der Technologien Novadel Pharma (AMEX:NVD) Biophan der Yakkommunikationen (NASDAQ:YAKC) (OTCBB:BIPH) (OTCBB:NNAN) Plasticon sind internationale (OTC:PLNI) Lebenwissenschaften (OTCBB:CBAI) Grant (OTCBB:GLIF) der gesamte Fall webcast und für 90 Tage durch Vcall an http://www.vcall.com/IC/ClientPage.asp?ID=99713&CID = und www.investrend.com vorhandenes. Dieser Fall wird von Tobin Smith u. ChangeWave, Charles Payne u. Wall Street Strategien, PeterLeeds.com, Wall Street Kalender, Forschung Investrend, BusinessWire u. Markt-Harmonik gefördert. Bogenkonferenzen werden auch von einem Feb. 23 und März 23, 2006 festgelegt. Die Firmen, die interessiert werden, an Kontaktbogen bitte darstellen an der [e-mail]-Anwesenheit bei den Bogenkonferenzen, geöffnet ist nur zu qualifizierten Investitionfachleuten. Das webcast ist für die Öffentlichkeit vorhanden. Diese Konferenz ist durch nur Einladung. Treten Sie bitte mit deutschem De La Roche bei 347-427-9052 oder Cindy Liang bei 347-252-4164 in Verbindung. Über Arch Arch Investment Conferences, Inc. bewirtet exklusive Fälle, damit Firmen an Fonds-Geschäftsführungen, an Analytiker, an Investmentbanker, an Vermittler und an andere Mitglieder der Investitiongemeinschaft anschließen. Bogen ist nicht nur eine Brücke zu den Firmen des Morgens, aber zu den Investitionideen von heute. SCHLÜSSELWORT des Besuchs www.archconferences.com: INDUSTRIECSchlüsselwort NORDAMERIKAS NEUES YORK VEREINIGTE STAATEN: DER TECHNOLOGIE-VERBRAUCHERCElektronik GOVE DER ALTERNATIVEN ENERGIE DER ENERGIE QUELLE: Bogen-InvestitioncKonferenzen, Inc.. KONTAKTCInformationen: Bogen-InvestitioncKonferenzen, Inc.. German de la Roche/Cindy Liang, 347-252-4164 [e-mail]

[arcoo]

meine Anwesenheit ist "verlangt worden"..., ... ist dieses ein guten Vorrat? ---------------------------------------------- http://www.pathways-to-peace.com/

[moneyonstreet]

#1226 von moneyonstreet 10.01.06 22:29:18 Beitrag Nr.: 19.645.472
Dieses Posting: versenden | melden | drucken | Antwort schreiben

seven companies... one of them ist glif ... another one is nnan... zu nnan a little bit info

financials
http://finance.yahoo.com/q/is?s=nnan.ob

marktet-cap 114 mio. euronen


just waiting... glif-market-cap round about 2 million usd

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

INVESTREND SIEHT DAS AUCH SO MI DER MARCET CAP ZU NNAN

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

NaturalNano Initiated At ‘Avoid/1’ Rating By Investrend Research Analyst Oren Meytes, CFA, Due To Current High Market Cap
January 13, 2006 (FinancialWire) (Investrend Research Syndicate) NaturalNano, Inc. (OTCBB: NNAN) has been rated Avoid/1 in an initiating Benchmark report due to the judgment of Investrend Research analyst Oren Meytes, CFA, MSc, that the shares of the company are currently at a high market capitalization, which the analyst said “already incorporates too many good things that have yet to happen.”...

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

MAL SEHEN... WAS INVESTREND VON GLIF HÄLT... DA IST NOCH NICHTS VON GOOD THINGS EINGESPREISST

[arcoo]

leute werden wünschen dises im depo zu haben

[arcoo]

Tendency MACD: bullish

[jaxn]

ausbruuuuuch

wir sind aus der 0,026er range mit erfolg ausgebrochen

[estewe]

back on the radar screen come on news

[jaxn]

[posting]19.753.868 von jaxn am 17.01.06 17:36:22[/posting]

na ja.....

wäre auch zu schön gewesen.

es heisst weiterhin

bitte warten

[arcoo]

nu bleib arca bid 999 wir sind die 0,03 nah und ab da bum

[moneyonstreet]

suuuuuuuuppppppppppoooooooooort strengthening

reeeeeeeeeeeesiiiiiiiiiiiistaaaaaaaance bröselt




2006 is GLIF-year

0,1 is coming soon

0,1 only first step of great north-climbing... anspruchsvolle bergsteiger sind damit nicht zufrieden

[moneyonstreet]

what a game

[moneyonstreet]

Posted by: momo player
In reply to: Hawkeiz who wrote msg# 17542 Date:1/17/2006 4:06:34 PM
Post #of 17550

just keep fillin them down here, GLIF lookin to run hard, imo.

[estewe]

heute sollten wir die 3 cent testen

[ollinbg]

allerdings! 3 cent sollten heute zumindest intraday drin sein. Level2 ist bis dahin quasi fast leer und das bid zieht auch schön nach!

[jaxn]

[posting]19.771.194 von ollinbg am 18.01.06 17:18:40[/posting]

das wird noch lange dauern

[estewe]

[posting]19.771.194 von ollinbg am 18.01.06 17:18:40[/posting]ja war kaum was im weg, nächste hoffnung die tagung von morgen

[estewe]

[posting]19.773.006 von jaxn am 18.01.06 19:09:32[/posting]stimm ich dir nicht ganz zu

die ersten aufträge der schnelltester wurden sofort angepriesen

und da waren wir bei mickrigen beträgen, es wird mit sicherheit mehr umsätze der tester geben.

der zeitpunkt für dengue fever ist aktuell gegeben und ohne ist das fieber nun auch nicht.

ergo - die katze muss aus dem sack auch wenn es keine millionen sind

[arcoo]

PPS sind doch schon mil

[arcoo]

was sagt euch wenn großer ARCA 999 bid level 2 so schön abend noch 0,03 oder 0,10 und dann ab zu 1 -2-3

[moneyonstreet]

please give me more support

[moneyonstreet]

two cent a week are 1 dollar in a year

go glif.. 2006 will be glif-year... 0,1 coming soon

[moneyonstreet]

i don`t need trader-flying.. i like two cent a week...

GLIF LONG

[moneyonstreet]

take it.. shake it... GLIF long... volume is strengthening with green pps show to momentum on the long term

[moneyonstreet]

TA... it will ride hard.. so i like it
make your own dd... perhaps only on TA... the rest of the story comes soonely via pr.. i think so

[moneyonstreet]

just my opinion!!!

Posted by: stockprofit2023
In reply to: RULiquid who wrote msg# 17700 Date:1/18/2006 5:14:47 PM
Post #of 17701


GLIF to try for the .03 again tomorrow,interest is growing along with the volume.Price is next!


GLIF will be in New York at a investment conference here is the link:

NEW YORK--(BUSINESS WIRE)--Jan. 9, 2006--Arch Investment Conferences, Inc., http://www.archconferences.com is proud to announce its conference series for the first 3 months of 2006 beginning Thursday January 19, 2006, 7:30 to 2:00PM, in New York at the Hotel Plaza Athenee, 37 East 64th Street, New York City. Tobin Smith of Change Wave Research & FOX NEWS Contributor, Charles Payne of Wall Street Strategies & FOX NEWS Contributor, and Peter Leeds of PeterLeeds.com are the featured guest panelists to whom companies will be presenting.------> Even more exposure!!!

[jaxn]

[moneyonstreet]

#1019 von moneyonstreet 20.12.05 23:50:29 Beitrag Nr.: 19.358.700
Dieses Posting: versenden | melden | drucken | Antwort schreiben

@ arcoo

2006 will be glif-year ... mark this post ... i say market-cap min. 50 mill. usd is no problem (no guarantee)... perhaps over 100 mill. usd with lucky punch... again: whats o/s by the time. GLIF is coming

0,1
0,5
1,0 arcoo long

[ollinbg]

[posting]19.773.006 von jaxn am 18.01.06 19:09:32[/posting]So lange dauert das nicht mehr jaxn!
Intraday gings schon wieder bis 2,75ct hoch.
Bis zur 3ct-Markte stehen auf Level2 nur noch 3 MM.

Das bid hat auch schön nachgezogen.
Bin sehr auf die nächsten Handelstage gespannt!

[fs2003]

19 Januar 2006 02:00 PM Zeitzone Berlin
Grant Life Sciences enters into Memorandum of Understanding (MOU) with U.S. State Department`s `Bio-Industry Initiative` (BII)
MURRAY, Utah--(BUSINESS WIRE)--Jan. 19, 2006--
`BII` designed to foster medical and other biological R&D in the former Soviet Union by converting former biowarfare scientists to productive peacetime activities





Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today the signing of a Memorandum of Understanding (MOU) with Dr. Peter Sveshnikov and Dr. Vsevolod Kiselev of the Russian Republic, for the in-licensing of certain of their technologies that are highly complementary to Grants` antibody-based test for detecting cervical cancer. The Sveshnikov/Kiselev technology comes to Grant from the U.S. State Department through its Bio-Industry Initiative (BII) program. The BII is designed to foster medical and other biological research and development in the former Soviet Union by converting former biowarfare scientists to productive peacetime activities.

Sveshnikov/Kiselev have developed an Enzyme-Linked Immunosorbent Assay (ELISA) to detect specific cancer-causing proteins from the human papillomavirus (HPV) -- the obligate cause of cervical cancer -- in the cervical mucous and cells (which make up liquid-based pap samples). The test utilizes certain monoclonal antibodies against these cancer-causing HPV proteins for detection. Thus far, the test is designed to detect cancer-causing proteins from HPV types 16 and 18 which, collectively, are responsible for most cervical disease. This type-specific antigen test, once fully validated and expanded to include additional types of HPV associated with cervical dysplasia and cancer, would be a very synergistic and complementary test to existing Pap technology. It will provide for very low-cost HPV testing as currently performed in Western countries, without the need for additional cervical specimens beyond what is now taken. In addition, large capital outlays would not be required, since most laboratories can readily do ELISA testing.

Sveshnidov/Kiselev have already tested their technology with 1000 Russian samples to confirm the potential of this technology. Grant will be further validating with more specimens from Russia and via the many cervical specimens obtained in the United States under its Institutional Review Board (IRB) approval in controlled clinical settings.

"Together, when validated, Grant will have two complementary cervical dysplasia or cancer diagnostic tests that will work on blood serum or cervical mucous and cells," said Dr. Hun-Chi Lin, President and Chief Scientist at Grant. "A blood-based test is eminently suitable for the 1.7 billion women worldwide who currently are not tested by Pap smear cytology. This inadequacy results in over 300,000 deaths per year. Meanwhile, a test employing cervical mucous or cells is readily fitting for Western medical venues, and has the potential of reducing costs dramatically when compared against those for current HPV DNA-testing. Furthermore, it could significantly reduce expenditures for follow-up referral procedures that turn out to be overwhelmingly negative, with billions of dollars per year in unnecessary medical expenses saved as a consequence."

About Grant Life Sciences Inc.

Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.

Forward-Looking Safe Harbor Statement

With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company`s operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company`s products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.

Kontakte
Grant Life Sciences Inc.
Don Rutherford, 949-521-1232
CFO

[ollinbg]

Das ask steht auf Level2 schon auf 2,7!
Und der Berg bei 3 ist auch schon ganz schön geschmolzen!

[jaxn]

sieht wirklich ganz gut aus für die nahe zukunft

[estewe]

[posting]19.786.257 von jaxn am 19.01.06 15:55:49[/posting]siehste hab geduld mit glif

[estewe]

das gap vom handelsbeginn ist nun lange genug zu
bewegt euch amis ich will nach dem mittag grüneres sehen !

[ggginger]

nix genaues passiert.die 3 cent wären mal wichtig,zefix

[estewe]

[posting]19.789.564 von ggginger am 19.01.06 19:20:06[/posting]zu mehr als kurzfristig die 3 hat es die arbeit mit den russen nicht gebracht
da muss es doch noch mehr geben !
mal abwarten ob sich die konferenz von heute mit den fox.tv jungs so positiv abzeichnet wie ich mir das erhoffe.
außerdem warte ich noch auf neue revenues von den schnelltestern.

[moneyonstreet]

what`s happened today or

- give me more support... very strong now

- news/pr is out.. coming more imo... glif building goes on

- mm uploading just started... see where the smart money flow.. chart give you the answers

2006 will be glif-year.. 0,1 coming soon ..take it and shake it for the long way to north

[moneyonstreet]

money flow index seems to me important

pps will follow it.. i think so

don`t believe mm-fake and share manipulation

[moneyonstreet]

five-day-rsi very undercooled for the moment

[moneyonstreet]

OT .. glif market-cap smart 2 Mio. usd

Posted by: manysevens
In reply to: RULiquid who wrote msg# 17911 Date:1/19/2006 4:51:00 PM
Post #of 17921

Love GLIF. Breakout from nice triangle .... nice smooth consolidation prior ... sitting atop 50dma ... and the 20dma ... golden box is evident ... good volume ... good news ... good product ... cheap stock ... let`s ride.

[moneyonstreet]

5. TUNE IN FOR TOBY ON FOX NEWS

Be sure to tune in to Fox News Channel this weekend and join Toby and the crew on "Bulls & Bears" for their weekly market roundtable as they kick off the Fox News Channel business block on Saturday, Jan. 21 at 10 a.m. Eastern. ("Bulls & Bears" replays at 4 p.m. Eastern, Sunday, Jan. 22 and 4 a.m. Eastern, Monday, Jan. 23.) Toby will also be appearing Saturday on Fox News Live from 12:20 p.m. to 5 p.m.

You can also catch Toby on "Your World with Neil Cavuto" Tuesday, Jan. 24, at 4 p.m.

Check your local cable listings or satellite guide to find the Fox News Channel location and times for your area. NOTE: These shows are NOT on your local Fox network station, but the Fox News Channel on your cable or satellite system (Channel 360 on DirecTV, Channel 205 on Dish Network). Keep in mind that these schedules are subject to change, and the Fox News Channel business block and other programming may be pre-empted for breaking news events.

[moneyonstreet]

low acton glif-board here.. so good..so bad...

come back on february.. so long...hold my xxx k shares for 0,1 and more glif go

[arcoo]

Berichten Sie Über Umreißen Zervikale KrebscVerhinderungcBemühungen Im ganzen Land, Medizinische Nachrichten Heute Thu, 2006 Zwischenbericht P.M. 4:18 Jan. 19 PST "2006 USA: Der ` Zustand ` der zervikalen Krebsverhinderung in Amerika, "Frauen in der Regierung: Der zweite jährliche allgemein Report findet, daß 20 Zustände und der Bezirk von Kolumbien Bemühungen in Richtung zum Ausrotten des zervikalen Krebses im letzten Jahr erhöhten. Die Entdeckungen des Reports basieren auf prüfenrate, Rate der nicht versicherten Frauen, Deckung der vorgerückten Siebungtechnologie in der Zustandgesundheitspflege

[arcoo]

Thursday, January 19, 2006

Yahoo! Alerts
Yahoo! Health - My Alerts - Edit Alert


Cervical Cancer Screening Rates Improving in U.S.
MedicineNet.com Thu, 19 Jan 2006 12:21 PM PST
Title: Cervical Cancer Screening Rates Improving in U.S. Category: Health News Created: 1/19/2006 1:58:00 AM Last Editorial Review: 1/19/2006 1:58:29 AM

Report Outlines Cervical Cancer Prevention Efforts Nationwide, USA
Medical News Today Thu, 19 Jan 2006 4:18 PM PST
"Progress Report 2006: The `State` of Cervical Cancer Prevention in America," Women In Government: The second annual nationwide report finds that 20 states and the District of Columbia increased efforts toward eradicating cervical cancer in the past year. The report`s findings are based on testing rates, rates of uninsured women, coverage of advanced screening technology in state health care

Cervical Cancer Screening Rates Improving in U.S.
HealthCentral.com Thu, 19 Jan 2006 3:36 AM PST
WEDNESDAY, Jan. 18 (HealthDay News) -- Efforts to screen American women for cervical cancer have gotten better, but improvement is still needed. That`s the conclusion of a new report that tracked recent progress on the issue state by state.

HPV Testing A Cost-effective Strategy For Women With Equivocal Cervical Screening Results
Medical News Today Thu, 19 Jan 2006 7:18 AM PST
A new study has found that using human papillomavirus (HPV) DNA testing to determine who should receive a cervical examination called colposcopy is a cost-effective management strategy for women with equivocal Pap test results known as ASCUS (atypical squamous cells of undetermined significance). The study appears in the January 18 issue of the Journal of the National Cancer Institute... click

[jaxn]

go glif go

[jaxn]

unterstützung steigt
liegt jetzt bei 0,023

wir steuern langsam auf die 0,030 zu

wenn wir die knacken gehts auf zur 0,050

gestern auch ein buy confirmed auf americanbulls

wird wohl bald hypen.

[g-broker]

das zieht sich aber die letzten tage jedesmal nur 0,005 im plus.da muss doc mal ein knall nach oben kommen.

[ollinbg]

[posting]19.863.262 von g-broker am 24.01.06 23:45:50[/posting]Ach, mit 0,0005 Plus jeden Tag könnte ich auch leben

[BirgiSennfeld]

Kann mir jemand sagen, warum bei onvista.de immer nur der kurs kurz nach 09.00 Uhr angezeigt wird, und danach nicht aktualisiert wird?

mfg

[Dauerpleite]

[posting]19.868.817 von BirgiSennfeld am 25.01.06 11:42:39[/posting]Weil in DE ganz selten gehandelt wird. So ist meistens kurz nach 9:00Uhr die erste und einzige Preisfeststellung.

[g-broker]

das wars wohl ,wird wohl abkacken.
werde morgen aussteigen aus dem scheiss.

[estewe]

hey noch einer da ?

money? arcoo? medom?


wenigstens giesser

[giesser]

schaue nur hin und wieder hier rein

das gepusche von money, arcor und co geht mir auf am arsch vorbei.

ich amüsiere mich über aussagen, das es aufwärts geht.

vielleicht kommt tatsächlich mal der euro.

aber nur nach einem r-split von 100000: 1

100000 alte aktien für 1 neue

aber die wird dann auch sehr schnell wieder fallen

allen investierten viel gedlg und noch mehr glück

[medom]

#estewe
bin schon seit einiger zeit raus, (-20%)
habe ich aber mit slwf wieder rausgeholt.
schaue ab und zu mal rein was gerade abgeht.
wenn das teil mal 10-20% hochgeht, holen sich die mm`s das sofort ab. muss schon eine galagtische news kommen,
um hier nachhaltig was in bewegung zu bringen.
viel glück noch

[estewe]

@medom ok viel glück für deine weiteren investments und lass dich mal wieder blicken



@giesser schön das du auch anders kannst
und nen netteren ton kennst

schönes we noch

[arcoo]

:coolgisser das wa nichts bin kein pus schönes wochenende 8k was hat das zu sagen lesen sie jedes wort langsam und verstehen sie es sind nur tage )-------------------------Sah jemand das webcast? Interessantes Material. Ich bin überrascht, daß niemand über es hier spricht. Die Firma sind auf Kalifornien umgezogen und Leute anstellen, um ihren Plan 06 durchzuführen. Sie haben ein Bündel Fotorezeptor geplant mit regelnden Unterordnungen in China, in Indien, in Mexiko und in Kanada und haben 8 Patente, die schwebend sind, passend, in den folgenden 6 Monaten genehmigt zu werden. Ihr CEO sagt, daß Einkommen $500K folgendes Jahr und $10 Million in 24 Monaten ist. Erster Fotorezeptor ist aus Montag mit Nachrichten auf einem eben angestellten Direktor des Marketings passend. Vor ich daß denke, dieses hat die Unterseite einigen Wochen gesehen und wird ständig sich erhöhen, während diese Firma vorwärts umzieht.

[arcoo]

Bilden Sie 8-K für BEWILLIGUNGSCLebencWissenschaften, Inc..


--------------------------------------------------------------------------------

27-Jan-2006

Ändern Sie im Buchhalter, in den Finanzberichten und in den Ausstellungen



Einzelteil 4,01. Änderungen in Registrants bestätigendem Buchhalter.
An Januar 24, 2006, Grant Life Sciences, Inc. entließ Russell Bedford Stefanou Mirchandani LLP als sein unabhängiger hauptsächlichbuchhalter. Wirkungsvoller Januar 24, 2006, engagierten uns wir Sänger Lewak Greenbaum u. Goldstein LLP als unser neuer unabhängiger hauptsächlichbuchhalter. Unsere Direktion hat die Entlassung Russell Bedford Stefanou Mirchandani LLP und die Verabredung vom Sänger Lewak Greenbaum u. Goldstein LLP als unsere neuen unabhängigen hauptsächlichbuchhalter genehmigt.

Nach Verabredung Russell Bedford Stefanou Mirchandani LLPs durch das Datum ihrer Entlassung an Januar 24, 2006, gab es keine Widersprüche zwischen unserer Firma und Russell Bedford Stefanou Mirchandani LLP auf jeder möglicher Angelegenheit, die unter Einzelteil 304 verzeichnet wird, unterteilen (a)(1)(iv) A bis E des vorgeschriebenen Sb, einschließlich der Bilanzierungsgrundsätze oder der Praxis, der Finanzberichtfreigabe oder Revidierungsbereich oder -verfahren, die, wenn sie nicht zur Zufriedenheit von Russell Bedford Stefanou Mirchandani LLP behoben werden, Russell Bedford Stefanou Mirchandani LLP veranlassen haben würden, Bezug auf die Angelegenheit in seinen Reports auf unseren Finanzberichten zu nehmen. Der Bericht über die Finanzberichte bereitete sich durch Russell Bedford Stefanou Mirchandani LLP während der steuerlichen beendenden Periode Dezember 31, 2004 enthielt einen Punkt in Bezug auf unsere Fähigkeit, als gehendes Interesse fortzufahren vor.

Vor engagierendem Sänger Lewak Greenbaum u. Goldstein LLP, berieten wir nicht Sänger Lewak Greenbaum u. Goldstein LLP betreffend ist irgendein:

1. die Anwendung der Bilanzierungsgrundsätze jede mögliche spezifizierte Verhandlung, entweder durchgeführt oder vorgeschlagen oder die Art der Bilanzmeinung, daß Macht unsere Finanzberichte gemacht wird und weder ein schriftlicher Report wurde zu unserer Firma zur Verfügung gestellt, noch war Mundrat, vorausgesetzt daß PricewaterhouseCoopers, das gefolgert wurde, ein wichtiger Faktor war, der von unserer Firma in zum Erreichen einer Entscheidung hinsichtlich der Buchhaltung, in zur Revidierung oder in zur finanziellen berichtenausgabe betrachtet wurde; oder

2. von jeder möglicher Angelegenheit, die entweder Thema des Widerspruchs oder Fall war, wie in Einzelteil 304(a)(1)(iv)(A) vorgeschriebenes Sb und die in Verbindung stehende Anweisung zu Einzelteil 304 des vorgeschriebenen Sb oder von des reportable Falls, als diese Bezeichnung definiert wird in Einzelteil 304(a)(1)(iv)(A) des vorgeschriebenen Sb erklärt.

Vor engagierendem Sänger Lewak Greenbaum u. Goldstein LLP, Sänger Lewak Greenbaum u. Goldstein LLP hat unsere Firma entweder nicht mit geschriebenem oder Mundrat versehen, der ein wichtiger Faktor war, der von unserer Firma betrachtet wurde, wenn es eine Entscheidung erreichte, um neuen unabhängigen hauptsächlichbuchhalter unserer Firma von Russell Bedford Stefanou Mirchandani LLP zum Sänger Lewak Greenbaum u. Goldstein LLP zu ändern.

Wir versahen Russell Bedford Stefanou Mirchandani LLP mit einer Kopie dieses gegenwärtigen Reports auf Form 8-K an Januar 25, 2006, vor seiner Archivierung mit der sek und verlangten, daß sie uns mit einem Brief versorgen, der an die sek angebend adressiert wird, ob, sie mit den Aussagen übereinstimmen, die in diesem gegenwärtigen Report auf der Form 8-K abgegeben werden, und wenn nicht, die Aspekte angebend, mit denen sie nicht sind. Eine Kopie des Buchstaben, der von Russell Bedford Stefanou Mirchandani LLP, datiert Januar 25, 2006 zur Verfügung gestellt wird, wird zu dieser Form 8-K als Ausstellung angebracht.





Finanzberichte und Ausstellungen des EINZELTEILS 9,01

Stellen Sie Buchstaben der Zahlbeschreibung 16,1 von Russell Bedford Stefanou Mirchandani LLP aus, datiert Januar 25, 2006.




--------------------------------------------------------------------------------

[fs2003]

Ich warte......ich habe zeit.....

[arcoo]

so das ist das letzte von mir long liebe investors kein zock --http://vcall.com/IC/index.asp?calDate=20060119 -- und das hört sich sehr gut an

[arcoo]

so das ist jetzt meine letzte meinung dazu alte news aber macht euch selber eure meinung --------große Fische pasen herauf ------ brechender Nachrichtenalarm des Marktimpulses für Montag, Sept. 26, 2005: CHDT -- Chinesisch-Bildete direkte handelnde Corp. Signs Multi-Million Dollarvereinbarung Chinas, 500 zu liefern Generatoren!

[ollinbg]

Grant Life Sciences Appoints Dr. Indira R. Pottathil as Director of International Marketing; Will Oversee Expansion into Asian Markets
1/30/2006 9:00:00 AM EST

Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today the appointment of the Company`s first Director of International Marketing: Indira R. Pottathil, Ph.D.

Since 1996, Dr. Pottathil has served as Vice President of Research & Development at biotechnology company AccuDx Corp., where she managed compliance efforts as well as development and production of in vitro diagnostic products. Dr. Pottathil began her career at the University of Bombay`s Cancer Research Institute, where she was a Senior Scientist for six years. More recently, she was employed for five years as an Information Scientist with Schering Plough. She earned her doctorate in Applied Biology at the University of Bombay. In addition, Dr. Pottathil served as a Postdoctoral Research Associate at The Jackson Laboratory (Bar Harbor, Maine) and was a Postdoctoral Fellow at Duke University.

"Dr. Pottathil is a very important addition to our management team," said Dr. Hun-Chi Lin, President and Chief Scientist at Grant Life Sciences. "One of her primary responsibilities will be to expand our capacity to serve various Asian markets. We already have begun generating revenues from sales in Asia of our rapid tests for Malaria and Dengue Fever. These products, along with rapid tests for HIV-1 and HIV-2 that also were acquired last year from AccuDx, represent an impressive product portfolio. We are very excited to have Dr. Pottathil on board to drive new-business development for Grant Life Sciences in Asia."

AccuDx Corp., based in La Jolla, Calif., was founded by Ravi Pottahil, Ph.D., one of the world`s leading authorities in the field of HIV/AIDS diagnostics and therapeutics. Under the agreement with AccuDx, Grant Life Sciences controls the exclusive rights to AccuDx`s rapid tests, as well as AccuDx`s proprietary colloidal gold reagent. In addition, the agreement established the right for Grant Life Sciences to manufacture these products in AccuDx`s `maquiladora`-modeled contract facility in Tijuana, Mexico, which is registered with the FDA and is ISO 9002-certified. Dr. Ravi Pottahil is assisting Grant Life Sciences in expanding its product line to include rapid tests for Hepatitis, Rubella, and other common diseases.

About Grant Life Sciences Inc.

Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.

Forward-Looking Safe Harbor Statement

With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company`s operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company`s products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.

[arcoo]

Beitrag Nr.: 19.947.155 was ich sage ,bin nicht da

[ollinbg]

[posting]19.953.397 von arcoo am 30.01.06 09:08:27[/posting]Habt Ihr Euch mal den das mal angehört?

Bis spätestens in 6 Monaten sollen Vertriebspartner für Asien gefunden werden!
In 2 Jahren 10Mio Umsatz!

[ollinbg]

[posting]19.969.500 von ollinbg am 31.01.06 09:46:21[/posting]Ups, was war das denn für ein Deutsch - ist wohl noch zu früh am morgen

Meinte den webcast...

[estewe]

[posting]19.969.500 von ollinbg am 31.01.06 09:46:21[/posting]na denn mal los glif

ich warte schon die ganze zeit auf ein update der testverkäufe

[ollinbg]

In dem webcast wird auch deutlich, dass in Asien ein enormer Markt für die Krebs-Teststreifen besteht.
Die Frauen dort lassen sich nicht bzw. sehr ungern beim Frauenarzt draufhin untersuchen. Die Teststreifen bieten somit eine einfache und vor allem im Vergleich zu anderen Untersuchungstechniken eine günstige Testmöglichkeit.
Der neue Marketing-Chef ist auf Asien spezialisiert und soll dort eine Partner-Suche vorantreiben. So wie ich es verstanden habe, soll in spätestens 6 Monaten auch vollzug vermeldet werden.

[arcoo]

ja aber krebs tester muß in übersee erscheinen und 8 pate...auch asien ist ein teil mexico und und und und die börse ni..es vor? alles kla warum machen mm den preis 0,02-0,022 ja ja große fische

[arcoo]

ollinbg deine frage lese news haben im oktober/nov 2005 angefangen mit einkommen 35000 $ 14 tage ! und jahoo 2004 sehe es dir an

[jaxn]

die 0,020 hat wieder gehalten.

die aktie will nicht mehr nach unten.

ich erwarte die 0,050 in den nächsten wochen.

[fs2003]

GLIF

[jaxn]

[jaxn]

[estewe]

na noch einer da?

heute haben wir mal überdurchschnittliches volumen. nach ner stunde 20min. ist bereits über die hälfte des tagesdurchschnitts gehandelt worden.

wäre mal zeit für ein revenue-update

[jaxn]

bin noch hier.
scheint sich ja wieder etwas zu bewegen.
hoffen wir mal auf news.

[jaxn]

[estewe]

[posting]20.221.235 von jaxn am 15.02.06 17:27:12[/posting]an der 2 cent-grenze gab es immer wieder käufe als wenn man sich positioniert

hoffen wir das beste

[jaxn]

geil.....

was geht da ab?

ist die warterei jetzt bald vorbei?

wurde ja mal zeit.

[estewe]

[posting]20.471.277 von jaxn am 02.03.06 18:30:12[/posting]wenn ich es wüsste würd ich mich bis an die zähne mit glif zuschmeissen.

auf jedenfall sauberes volumen mit knapp 13 Mio.

wär zu schön allerdings hat glif das vor gut3-4wochen schonmal gemacht und is denn wieder auf den boden der 2 cent zurück.

[estewe]

[posting]20.471.277 von jaxn am 02.03.06 18:30:12[/posting]gibt es arcoo noch und money ? mal was von denen gehört?

[jaxn]

[posting]20.472.431 von estewe am 02.03.06 19:14:28[/posting]money hat schon angekündigt dass er sich ein paar monate nicht mehr blicken lässt und arcoo....
wer weis das schon.
is mir aber egal.
hauptsache es kracht mal ordentlich hier.

[estewe]

[posting]20.472.620 von jaxn am 02.03.06 19:21:24[/posting]da hätt ich auch nix dagegen, hoffentlich gibts ein update der schnelltestverkäufe.

[jaxn]

buy confirmed auf americanbulls.

The recent bullish formation leading to the BUY-IF signal is confirmed today. The market seems ready for a new bullish move. It opened today with a gap-up and the day’s activity resulted in a close higher than the open. This is one of our valid confirmation criteria.

schaun wir mal was der markt heute macht.

[jaxn]

das sieht verdammt gut aus.
vielleicht kommt jetzt echt bald der big bang.


wenn wir heute über dem sk von gestern bleiben sehe ich morgen einen grossen tag auf uns zukommen....
wer auch immer noch dabei ist.

[estewe]

hoffe du meinst montag hab morgen keine zeit

GLIF 0.0299 +0.0100 0.023 0.031 0.022 0.0292 0.0299 13,009,642

[jaxn]

[posting]20.495.418 von estewe am 03.03.06 20:01:01[/posting]verdammt.
wir haben ja wochenende.
hehe

[estewe]

ach ja den großen tag natürlich noch mit guter pr-arbeit würzen!

[jaxn]

[jaxn]

was für ein nettes ende.
das wird noch krachen am montag.

[moneyonstreet]

[posting]20.497.928 von jaxn am 03.03.06 22:07:32[/posting]hallo jaxn,
hallo gliffers,

as i said.... coming back few weeks later. every time still on this board, but only posting on rb-board in us where the music plays. now its time for the shorty glif-game.. and i think you`ll be have much fun in short opinion but even more on the long term. all about the blockbuster-products is said... assigned patents coming nearer and with this also revenues. 2006 will be glif-year with short-term-target min. 0,1 and 0,5 on the long term for clever-gliffers. this is the begining of a great medical-story... show to the chart



jaxn, thx for posting on this board including rt-chart during the "glif-sabbat-days". better times are rolling on... insiders have the ear/nose on the front. oki doki

from
m.o.s

[jaxn]

[posting]20.498.639 von moneyonstreet am 03.03.06 22:54:57[/posting]welcome back money.
hoffe es geht in dem stil weiter.

[jaxn]

noch jemand dabei?

da herrscht ja die reine kaufpanik....

kz 0,06?

[jaxn]

wenn die 0,032 geknackt werden is der weg frei bis 0,06

[estewe]

immernoch dabei aber selten zeit.

als anfang würde mir reichen eine neue basis in den höheren 2cents gefunden zu haben. die nächste pr sollte denn genug treibstoff für höhere sphären geben.

[jaxn]

geil....
es will weiter steigen.


morgen die erste echte explosion?

der widerstand bei 0,32 wird fallen.......er mussssss

anschieeeeben.

[jaxn]

[jaxn]

[jaxn]

wer will noch mal, wer hat noch nicht.
heute könnte es was werden mit den überwinden der 0,032.
auf steigende kurse

[giesser]

Detailed Quote Snapshot 03/07/2006 10:31 AM

Last: 0.0445 glif - GRANT LIFE SCIENCES INC

Change: +0.01 %

Change: +33.33%

High: 0.045

Low: 0.029

Volume: 8,886,961

[cht2]

Hallo zusammen,
bin neu hier im Board, aber schon lange bei Glif investiert.
Was geht dann gerade hier ab? Die sind ja kaum zu stoppen.
Stehen News an? Weiss jemand mehr?
mfg

[jaxn]

weeeeeeehhhhh haaaaaaa
jeahhhhhhhh

auusbruuuuuuuch

[HoTsTePPa.]

Hammer

[ggginger]

ENDLICH ES GEHT LOS!!!!!!!!!!!!!!!!!!!!!!!!!

[ggginger]

AUF ZU NEUEN HÖHEN;ich glaub wir haben lange gewartet.

[Spitzenrolli]

Gibt es News? Oder was ist los?

[Spitzenrolli]

Vor allem, in FFM gibt es noch günstig Stücke. Da wird der Ausbruch noch gar nicht wargenommen.

[cht2]

[posting]20.557.514 von Spitzenrolli am 07.03.06 16:49:27[/posting]Stimmt, lt. meinem Realtime-Orderbuch stehen 100.000 zu 0,047 Euro drin.

[efex]

glückwunsch an euch

[jaxn]

ich habs euch doch gesagt.

es hat stark nach ausbruch gerochen die letzten wochen.

gratulation an alle investierten

[ggginger]

wir knappern an den 0,08 das ist der hammer +150%

[Spitzenrolli]

Da ist was im Busch. Bei den Umsätzen. Da wissen einige schon wieder mehr....

[HoTsTePPa.]

Aktuell 103 %

Spitze war irgendwas über 180 %. <-- Konnte da jemand aussteigen?

[giesser]

ja ich

habe ich ffm zu 0,06 verkauft

[HoTsTePPa.]

[posting]20.558.176 von giesser am 07.03.06 17:21:39[/posting]GW

[jaxn]

habe 2 drittel zu 0,077 an den mann gebracht

aber muss ja nicht sein das es schon das ende der fahnenstange ist

[giesser]

danke

werde aber später wieder einsteigen

denke wir werden noch mals sehr günstige einkaugfsgelegenheiten bekommen

[jaxn]

musst aber bald einsteigen.
so ein ausbruch der über 4 tage geht ist nicht so leicht zu bremsen.
da werden erst einige aufmerksam.

glif wird uns die nächsten tage noch freude bereiten.

[giesser]

der anstieg war ungesund

ausserdem ist ein hoher verkaufsdruck bei 0,07 zu erkennen.

abwarten wie es ausgeht

habe meine schafe erst einmal ins trockenen gebracht

[jaxn]

na das interesse scheint nach wie vor hoch zu sein.
da gehen ordentlich teile über den tisch
wahnsinn.

könnte gerade erst der anfang sein.

geilll

[jaxn]

[giesser]

frage an die experten:

wie hoch ist denn die börsenkapitalisierung?

meine information sagen etwas über 58.000.000 shares

ist diese info korrekt?

[Boersenolly]

StammdatenWertpapiertyp
Auslandsaktie

Marktsegment
Freiverkehr

Branche
--

Geschäftsjahr
--

Marktkapital.
3,48 Mio. EUR

Streubesitz
--

Nennwert
--

Stücke
94 Mio.

Symbol
G9E.FSE

ISIN
US3881131029

WKN
A0F6J8

[Priscilla]

Ich habe 67 Mio gelesen.

MK 281400$

[Boersenolly]

laut comdirectbank

[Priscilla]

[posting]20.562.480 von Boersenolly am 07.03.06 21:25:06[/posting]Sorry, was ich geschrieben habe ist natürlich Schwachsinn.
Wenn bereits 116 Mio Aktien gehandelt wurden sollten die bisherigen Zahlen natürlich falsch sein.

Kommt nochmal ein wenig hoch.

akt. 0,0469

Was geht denn nun hier ab?

[jaxn]

laut raging bulls board hat sich stockster mit glif aktien eingedeckt. weiss aber nicht ob schon eine empfehlung zu glif rauskam.
auf jeden fall steht glif jetzt im fokus der trader.
kann im günstigen fall locker auf 0,18 steigen.
schaun wir mal was heute rauskommt. es scheint sich ausserdem ein boden um 0,04 gebildet zu haben.

[estewe]

so back to the roots alter boden wohl gleich neuer boden.

im übrigen ist die stockster empfehlung geschichte die war nicht mal 2 stunden online

[HoTsTePPa.]

Bei Stockster konnte man in einer Stunde über 100 % machen.

[Priscilla]

So ist der Spuk nun vorbei?

Vorgestern heftiges Volumn und intraday 0,085$. Gestern ein fünftel des Umsatzes und SK 0,026$.
Ob der Stcokster-Zwei-Stunden-Push ein solches Volumen verursachen konnte?

Bin mal gespannt wie es hier weitergeht. Die Quartalsberichte lesen sich ja nicht grade wie der Beginn einer Riesensache, sondern eher kämpft man von Quartal zu Quartal um die Fortführung des ganzen.

52W-Hoch bei 0,55$ auch interessant. Warum stand das Teil mal so hoch?

[jaxn]

schade
scheint alles wieder beim alten zu sein.
bei 0,019 steig ich vielleicht wieder ein.

[DjSmoli]

GLIF wurde 38 Tage lang geshortet nun ist wieder ein Run angesagt:

GLIF GRANT LIFE SCIENCES INC OTCBB 38

http://www.nakedshortlist.com/selectbysymbol.html#G

Like so many other stocks recently (actually from January) GLIF has rallied and allowed for some profit taking --- has now reached the "muddy reversal from a pullback" zone and has fallen to the 38% Fib retracement level, where it appears to have found support.

All indicators that count are pointing to the normal "secondary pop" that strong stocks "normally" go thru (stock rallies, pulls back to the "zone" and/or the 50% to 38% Fib level, and goes for another ride)

this "secondary pop" is what allows me to continue trading a stock all week, as there is no need to go running after a new one when an older one will do just as well and GLIF is doing just what i like and what im used to !

the RSIWLR is presently showing a day and 2/3 of movement, which translates into a very nice monday and a "probable" gap, run and selloff on tuesday, by 11 or 12 oclock, with a "possible" stretch to 2:30 which i wouldnt count on!

Unless things change, for safety, figure on taking profits tuesday morning and watch for the stock to form a double top, not being able to break out past its previous rally high. At that point, the stock will go back into DOWN elevator mode, and we dont want to get stuck in that situation !

Now, there seem to be some BIG players in the most recent runup stocks, and they MIGHT want to take this stock higher ---- but i dont speak Arab, and they dont email me, so I dont know where they will be bailing this time --- will figure resistance points and see if i can make a legitimate prophesy on what i believe they may do this time around !

no matter what happens, safety lies in leaving the stock by 11am on tuesday. If it continues up, one can always simply re-enter the stock.

NOT MAKING IT TO THE VERY TOP OF THE RUN simply means you left some money on the table. GOING PAST THE TOP and into the downside means you have now given back money, and may be heading for a loss ----- dont let greed leave you as a "STUCKHOLDER !" Sell when you have a percentage of profit on the table, and go on to the next running stock --- lately theyve been showing up with amazing frequency !

[Priscilla]

Volumen zieht etwas an.
> 1 Mio. nach 30min.

Die Klitsche müsste in dieser Woche auch mit Zahlen kommen. Mal schaun ob sie dem Totengräber etwas weiter von der Schippe springen konnte.
Sollte der heutige Kursverlauf eigentlich vorweg nehmen.

[jaxn]

[jaxn]

[moneyonstreet]

moin, moin

glif seems to be a little bit cold now.. don`t know where the pullback end.. bet that it go at least to 0,05 accumulation is at the end and finishing mou should not be worth to glif-co.

[moneyonstreet]

bottom line works... something interesting coming up like closing mou... who knows

http://stockcharts.com/c-sc/sc?chart=GLIF,uu[h,a]daclyyay[pb…

[fs2003]

05/16/2006 (13:05 ET) GLIF: Filed New Form NT 10-Q, Quarterly Report to be Filed Late

[moneyonstreet]

!!!!!!!! NEWS !!!!!!!!!!!

GLIF news (PR NEWSWIRE) Grant Life Sciences Chairman Featured in Exclusive Interview With
WallSt.net
Grant Life Sciences Chairman Featured in Exclusive Interview With WallSt.net

NEW YORK, July 7 /PRNewswire/ -- On July 5, Stan Yakatan, Chairman of
Grant Life Sciences, Inc. (OTC Bulletin Board: GLIF) updated the investment
community in an exclusive interview with www.wallst.net . Topics covered in
the interview include an overview of the Company and the markets it serves,
recent press releases, current capitalization, upcoming strategic and
financial milestones.
To hear the interview in its entirety, visit www.wallst.net , and click on
"Interviews." Interviews require free registration, and can be accessed
either by locating the respective company's ticker symbol under the
appropriate exchange on the left-hand column of the "Interviews" section of
the site, or by entering the respective company's ticker symbol in the Search
Archive window.
About Grant Life Sciences, Inc.
Grant Life Sciences, Inc. develops products to improve the efficiency of
detecting and diagnosing cervical cancer, including a sensitive, reliable,
non-invasive, point-of-care test. The diagnostic assay being developed by the
Company has shown promise in detecting cervical cancer and its precursors, a
disease that kills in excess of 300,000 women annually. According to the CDC
there are currently more than 120 million cervical screening tests
administered annually in the U.S. and Europe. In developed nations more than
120 million eligible women, 20 years old and above, still do not get Pap
smears, and globally more than 1.7 billion over the age of 20 have never been
checked due to cultural, religious or economic reasons. Further information
is available at: www.grantlifesciences.com .
About WallSt.net
www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly
owned subsidiary of Financial Media Group, Inc. The website is a leading
provider of financial news, media, tools and community-driven applications for
investors. www.wallst.net offers visitors free membership to its in-depth
executive interviews, exclusive editorial content, breaking news, and several
proprietary applications. In addition to its website, WallStreet Direct
organizes investor conferences, publishes a newspaper, and provides multimedia
advertising solutions to small and mid-sized publicly traded companies. We
are expecting to receive one hundred seventy five dollars from Grant Life
Sciences, Inc. for the dissemination of this press release. For a complete
list of our advertisers, and advertising relationships, visit
http://www.wallst.net/disclaimer/disclaimer.asp
(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)

Contact:
Nick Iyer
Digital Wall Street, Inc.
1-800-4-WALL-ST
SOURCE WallStreet Direct, Inc.


Contact Information:
Nick Iyer of Digital Wall Street, Inc., +1-800-4-WALL-ST

WebSite:
http://www.grantlifesciences.com
*** end of story ***

[SharpRatio]

Ja, und total unbeachtet. Tu mir einen Gefallen und hör Dir mal das Interview an!! GLIF ist DIE Mega-chance der kommenden Tage.

Verbesser mich, wenn ich falsch liege, aber der CEO kündigt im letzten Abschnitt des Interviews

Den Mega-Blockbuster in Form eines Krebsschnelltestes an

Ca. 2 Mrd "Kundschaft" pro Jahr, ein Test soll 25 - 30 Dollar kosten.

60 Mrd. Revenue ist natürlich quatsch. Das Zeug muss ja jemand bezahlen. Aber sicher ist, dass der Markt gigantisch sein wird. Außerdem ist der Test technisch verbessert und bietet Vorteile ggü. dem antiquierierten Testverfahren.

[SharpRatio]

Aktuell hat GLIF eine Market-Cap. von 1,8 Mio. Wenn der Test kommt sollte sich die Market-Cap. deutlichst erhöhen. Ich hab noch 80 k im Depot. Geilooooooo

[SharpRatio]

Antwort auf Beitrag Nr.: 22.463.838 von SharpRatio am 08.07.06 13:25:30

Ich hab jetzt einiges an Fakten zusammengetragen. Bei Glif steht jetzt die brandheiße Phase an. Das geht eindeutig aus dem Interview hervor. Ich bin sicher, wer jetzt investiert hat die größten Chancen.

Ich bin zu 4 Cent rein. Selbst mit der Position ist noch einiges drinnen. Schwer zu sagen, wo GLIF nach Produkteinführung stehen wird. Wirklich schwer. In diesem Markt müsste die Market-Cap mind. auf 50% des Umsatzes klettern. Market-Cap. aktuelle 1,8 Mio. Schwer zu sagen, wie hoch der Umsatz genau sein wird, aber ich denke auf jeden Fall im dreistelligen Mio.Bereich, dann müsste sich der Kurs verzwanzigfachen.... mmhhhh... Ja, ich werd meine alte Postion aufstocken und nochmal verbilligen. Ich denke, der Zeitpunkt war nie besser als jetzt. Hat schonmal jemand ins Interview reingehört??

Leider wurde es zum Handelsende veröffentlicht, so dass dieses Interview kaum jemand mitgehört hat.

[moneyonstreet]

Antwort auf Beitrag Nr.: 22.474.011 von SharpRatio am 09.07.06 09:33:31

Ich hab jetzt einiges an Fakten zusammengetragen. Bei Glif steht jetzt die brandheiße Phase an. Das geht eindeutig aus dem Interview hervor. Ich bin sicher, wer jetzt investiert hat die größten Chancen.

Kann dem nur zustimmen, es dürften bis Ende des Jahres fette news auf den Markt kommen, u.a.

- Verkäufe ACCUDX Produkte (ab 7/06 beginnend; möglicherweise fetter Mio. Stück Auftrag)... neue Vertriebs-Chefin is in process of signing several international contracts !!!!

- Ausweitung Produktpalette ACCUDX

- Closing russian-MOU and Israel-MOU in den nächsten Monaten 2006

- Marktreife cervical-cancer-test ab Ende 2006 erwartet

Ich denke, 200-Tage-Linie ist bald fällig und dann gilt der Blick ganz anderen Kursregionen.

[moneyonstreet]

[SharpRatio]

Das echte Kursziel von GLIF fernab jeder schätzung. Ich werde mich daher nicht damit befassen. Klar ist, dass der Markt weltweit so um die 10 Mrd. Dollar groß ist. Der alte Test hat ausgedient, so dass GLIF in einen völlig freien Markt stößt. Bei einer Market-Cap. von nicht einmal zwei Mio. kann sich jeder ausmalen, wo die GLIF-Kursnotiz bald stehen wird.

[as25]

Hier die Abacho Übersetzung von Spanisch in Englisch und Englisch in Deutsch:
Nicht fehlerlos wie bekannt, aber das Übernahmeangebot wird klar definiert. Und auch der Übernahmepreis von 0,10 Dollar wird erwänt.

Ist doch jetzt alles klar mit der Nachricht

Lissabon - Zur Quelle von Banco Espirito Santo (BES) sagte heute, dass Banco Espirito Santo der Übernahme zu Grant Life Sciences, Inc Banco Espirito Santo (BES) starten wird, notifie nächsten Freitag die portugiesische Staatssicherheitsmarktkommission (CNMV), dessen es bereit war, auf die Bedingung zu minimalem Annahmeniveau von 75 % zu verzichten, dem sein öffentliches Angebot für den Erwerb von Anteilen von Grant Life Sciences, Inc unterworfen war, in Betracht ziehend, dass die erhaltene Antwort genügend sein wird, um das durch das Übernahmeangebot verfolgte Geschäftsprojekt zu entwickeln. Banco Espirito Santo (BES) wird zum Übernahmeangebot für Grant Life Sciences, Inc mit der Zahlung des US-Dollars von 0.10 $ für jeden losfahren, dass Antwort auf, um Angebot zu neigen, dieses anfängliche Angebot die Grenze des Preises des US-Dollars von 0.12 $ für jeden Anteil der Gesellschaft erreichen konnte. Über Banco Espirito Santo: Experte einer der stärksten und traditionellsten Spieler auf dem portugiesischen Markt, Banco Espíritos Santo, gegründet 1884, ist Portugals führender franchize, wenn es Sie essen, um Sie Banken zu berauben. Sein Ruf ist jedoch durchquerte Grenzen, die Espírito Süßkartoffel von Santo international anerkannt und respektiert machend. In der vordersten Reihe des Internationalen Geschäfts zu sein, ist bestimmt eines der Ergebnisse, die wir behalten wollen. Unsere weit verbreitete Anwesenheit über den Erdball, in mehr als 50 Städten in 17 Ländern, macht uns die internationalsten von portugiesischen Banken und erlaubt am wichtigsten unseren Kunden - Personen, korporativ, Institutions- usw. - sich auf unsere Fähigkeit völlig zu verlassen, ihren Bankverkehrsvoraussetzungen in verschiedenen Erdkunden zu dienen. Finden Sie heraus wohnt über unsere Internationale Anwesenheit, und wie es auch verfolgt, vom Vorteil zu Ihrer Einrichtung sein. Trotz der Tatsache, dass zur großen Zahl unserer internationalen Einheitspflüge tief verbunden mit der Bestimmung von Dienstleistungen zu portugiesischen Emigrant-Gemeinschaften auswärts BES Gruppentätigkeiten Ass pflügen, änderte Experten seine globale Ausbreitung. Zur Liste der relevantesten internationalen Tätigkeiten hilft Zusammenstellung des breiten Spielraums der globalen BES Anwesenheit: Dienstleistungen zu Emigrant-Gemeinschaften (Kontoöffnung, Sparkonten, Überweisungen

[sonnenenergie]

Antwort auf Beitrag Nr.: 22.486.463 von SharpRatio am 09.07.06 19:27:32

Genau! Ich geb meine Aktien nicht her! Eher nutze ich die Ruhe vor dem Sturm und kaufe günstig nach!
Noch in diesem Monat geht`s UP und ich kann warten, und das sollte man können, wenn man gewinnen will -> nach dieser wichtigen Aktie werden sich noch viel mehr in die Höhe strecken! Wait or Buy

[physik]

Antwort auf Beitrag Nr.: 22.539.205 von as25 am 12.07.06 11:25:31

die Quelle war aber windig.
Das Übernahmegerücht ist eine Ente. Schon deswegen, weil niemand bei einem Kurs von 0.02 ein Übernahmeangebot von 0.1 veröffentlichen würde.
Ist doch nicht nötig, hier mit solchen Windeiern zu argumentieren.

[physik]

was mich etwas beunruhigt:
es gibt 1.5Mio shares. Anfang Juni hat sich GLIF die Aufstockung auf 7.5Mio genehmigen lassen.
GLIF hat 5 Mitarbeiter.

Kann mich jemand beruhigen?

[physik]

Antwort auf Beitrag Nr.: 22.564.528 von physik am 13.07.06 13:19:37

sorry, tippfehler:
es gibt 150Mio shares und die sollen auf 750Mio aufgestockt werden.

[david1]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[lupos13]

Es geht wieder los !

[rizz]

Diese "Übernahmemails" sind ein fake. Die tauchen überall mal auf, um den Kurs interessant zu machen. Die machen sich nicht mal die Mühe, die Bank zu wechseln. Es ist immer die gute alte portugisische Bank. Macht euch mal den Spaß, und ruft in Portugal bei der Bank an. Die sprechen da sehr gut englisch und nach 5 Minuten hat sich der ganze Spuk aufgelöst.
Ergo: Keine einzige Minute damit investieren...

Rizz

[guru5]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Ju-Lain]

test.de

[waxweazle]

Abstimmung Läuft bis 15.10.06 ( Sonntag ) 23.00
Die Aktie die die meinsten Stimmen bekommt wird eine Chartanaylse angefertig und veröffentlich.

Hier der Link zum Stimme abgeben

http://www.wallstreet-online.de/community/thread/1087751-1.h…

1 GRANT LIFE SCI.
2 PATRIOT SCIENT. DL
3 DE BEIRA GOLDFIELDS
4 PTS INC. NEW
5 BETONUSA AG
6 BIOPHAN TECHNOLOG.
7 ENERGULF RESOURCE…
8 GREAT WEST GOLD INC.
9 GAMEZNFLIX INC.
10 BLUE PEARL MINING

[Scat]

Antwort auf Beitrag Nr.: 22.564.528 von physik am 13.07.06 13:19:37

Genehmigt heißt nicht gleich ausgegeben.

Es ist durchaus üblich, dass mehr Aktien genehmigt als ausgegeben
sind...im Falle einer Kapitaleröhung kann die Firma dass dann
ohne isch erst nochmal neue Aktien genehmigen zu lassen

[zapad]

Antwort auf Beitrag Nr.: 24.804.012 von Scat am 23.10.06 18:06:21

in diesem Thread sind scheinbar nur die Vernünftigen!
Angenehm!!

[SCP]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[zapad]

Antwort auf Beitrag Nr.: 25.366.585 von SCP am 13.11.06 19:54:42

was willst denn damit sagen?
Verlangt doch niemand, daß Du dich ärgerst.
Versteh Dich nicht.

[Kjo_CBR]

Antwort auf Beitrag Nr.: 25.371.813 von zapad am 13.11.06 22:24:05

Benutzername: SCP
Registriert seit: 24.10.2006 [ seit 20 Tagen ]
Benutzer ist momentan: Offline seit dem 13.11.2006 um 22:26
Erstellte Themen: -

[nbielfeldt]

Antwort auf Beitrag Nr.: 25.374.246 von Kjo_CBR am 13.11.06 23:48:36

sind doch seit tagen basher am WERKEN ;-)

[klr]

Grant life ist ein OTC-Luftschloß!

Der Zock neigt sich dem Ende

KLR

[as25]

Es ist sehr negativ zu bewerten, daß es nötig ist wieder einmal von Übernahmeangeboten zu reden oder schreiben.
Wenn der Wert soviel Potential hat, wäre das nicht nötig !
Aber diese Art Meldungen hält eine Investition von Neueinsteigern
garantiert ab, und macht GLIF immer mehr zur Zockeraktie.

Traurig auf diese Art zu pushen

[zapad]

Antwort auf Beitrag Nr.: 25.411.303 von klr am 15.11.06 14:56:48

das ist ein Widerspruch, denn ein Zock muß wieder runterkommen sonst läßt sich kein Geld verdienen.

Ein guter Zock muß einen günstigen Einstieg bieten, um nach bzw. während eines weiteren Anstiegs, Gewinnmitnahmen zu gewähren.

einmal rauf und runter ist gar nichts.

[wallyonline]

Antwort auf Beitrag Nr.: 25.411.303 von klr am 15.11.06 14:56:48

Du meinst wohl weil du mit Patriot Schiffbruch erlitten hast muß es hier auch so sein ?
Da irrst du...

[SCP]

Antwort auf Beitrag Nr.: 25.366.585 von SCP am 13.11.06 19:54:42

Nun, hatte ich RECHT

[awsx]

Hauptthread geschlossen wegen .....?

[fab35]

Antwort auf Beitrag Nr.: 27.678.658 von awsx am 13.02.07 13:07:24

Es ist wirklich erstaunlich was dieser MOD für ein Maß anlegt.
Hausmannskost, Unkenhorst; SCP und Konsorten bashen hier auf Teufel komm raus, beleidigen und labern nur inhaltloses Zeug und irgend so ein MOD macht den Thread zu weil es mal ein wenig spaßig hergeht wenn die o.g. mal nicht da sind.
UNFASSBAR
Grüße
Fab

[Brooklin]

Antwort auf Beitrag Nr.: 27.678.882 von fab35 am 13.02.07 13:16:51

Korrekt ist eine Sauerei

[miwl]

Antwort auf Beitrag Nr.: 27.678.882 von fab35 am 13.02.07 13:16:51

*anschließ*

[AlexanderDD]

das ist wirklich nicht normal, was die sich blos einbilden tztztz

[MaatMod]

@al Guten Tag

sollte sich hier Eure Protestwelle fortsetzen
werde ich auch diesen Thread hier schliessen.

MfG
MaatMOD

[FuZerL]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[fab35]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[1bull007]

Aber wieder zurück zu GLIF:

Wie viele Tests sind denn nun ready to the market ?????

Bitte um Antwort.
habe leider keine Antwort von Dr. Lin bekommmen.
bezw. er ist dieser Frage ausgewichen.


Aber Kochrezepte, schöne Frauen, Brasilien, Essen, Trinken und Musik sind ein elementarer Bestandteil des Lebens.

Wir werden es schaffen liebe GLIF Freunde !

[FuZerL]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Brooklin]

Antwort auf Beitrag Nr.: 27.678.993 von MaatMod am 13.02.07 13:22:18

Schonmal was von DEMOKRATIE gehört, wo lebt Ihr

[seppelbroker]

Antwort auf Beitrag Nr.: 27.679.118 von Brooklin am 13.02.07 13:28:41

müsste MadMod heißen

[Gilhaney]

Antwort auf Beitrag Nr.: 27.678.882 von fab35 am 13.02.07 13:16:51

Hallo fab35,

was mich immer wieder überrascht ist die offenbar begrenzte oder zumindest rettungslos polarisierte Wahrnehmungsfähigkeit eines Teils der Teilnehmer. Oft genug wird manchen Usern unterstellt, sie wären beleidigend. Ulkigerweise wird dies ausgerechnet denjenigen nachgesagt, die hier die übelsten Beleidigungen an den Kopf geworfen bekommen. Wobei der Griff in die Schublade der Fäkalsprache manchem deutlich einfacher gelingt, als einer Kritik kompetent zu begegnen.
Dieser Mangel an Präzision und Niveau in Beobachtungs- und Ausdrucksfähigkeit muss mich hoffentlich nicht auf die Urteilsfähigkeit der Optimisten bezüglich der Entwicklung von Grant schliessen lassen... Wäre schade um das Geld.


Gruß
Gilhaney

[FuZerL]

Antwort auf Beitrag Nr.: 27.679.087 von 1bull007 am 13.02.07 13:27:11

Soweit ich weiß, nur das "AccudX" Produktportfolio.

Malaria rapid diagnostic tests
rapid tests for Dengue Fever, HIV-1 and HIV-2, among others


Und der HPV test wird bald soweit sein, denke ich.

[1bull007]

Hallo Leute !

Es hat gar keinen Sinn hier gegen denn Mod zu kämpfen, denn wir sind nur in GLIF interessiert.

Wir danken Wallstreet, dass sie so ein gutes Portal allen zur Verfügung stellt.

Aber wir möchten wieder über unsere Aktie reden,

Bitte bitte bitte lieber Mod, wir haben doch nicht angestellt, bitte wieder alles freigeben.

Da gibt es viel schlimmere Typen als wir es sind.

[1bull007]

Antwort auf Beitrag Nr.: 27.679.211 von FuZerL am 13.02.07 13:33:34

Das wären dann 3 Tests.

Bis jetzt hat GLIF nur den Malariatest vekauft.

Zeit andere zu verkaufen.

[FuZerL]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[fab35]

Antwort auf Beitrag Nr.: 27.679.206 von Gilhaney am 13.02.07 13:33:22

....und was willst du jetzt ?

[Gilhaney]

Antwort auf Beitrag Nr.: 27.679.331 von fab35 am 13.02.07 13:38:57

Hallo fab35,

erkläre Dich etwas genauer.


Gruß
Gilhaney

[fab35]

Antwort auf Beitrag Nr.: 27.679.366 von Gilhaney am 13.02.07 13:40:59

Red doch mal nicht ganz so geschwollen....

Ist aber auch egal. Thema durch.

Gruß
fab

[Gilhaney]

Antwort auf Beitrag Nr.: 27.679.410 von fab35 am 13.02.07 13:43:27

werd´mich hüten...

[seppelbroker]

also, hier werden gnadenlos Postings gelöscht, ich find das unmöglich!

[scsimodo]

Antwort auf Beitrag Nr.: 27.679.466 von seppelbroker am 13.02.07 13:46:18

.
Nicht ist unmöglich...
M...M...

.

[Gilhaney]

Antwort auf Beitrag Nr.: 27.679.466 von seppelbroker am 13.02.07 13:46:18

Hallo seppelbroker,

warum ? Der Thread hat´s eigentlich dringend nötig.

Gruß
Gilhaney

[seppelbroker]

Antwort auf Beitrag Nr.: 27.679.509 von scsimodo am 13.02.07 13:48:53

[Brooklin]

RT 0,06

[seppelbroker]

Antwort auf Beitrag Nr.: 27.679.944 von Brooklin am 13.02.07 14:11:04

und Ask auf 63 hoch

[Aktienspekulant]

Benutzername: FuZerL (gesperrt)
Registriert seit: 02.12.2006 [ seit 73 Tagen ]
Benutzer ist momentan: Online seit dem 13.02.2007 um 08:38
Erstellte Themen: -
Erstellte Antworten: 447 [ Durchschnittlich 6,1424 Beiträge/Tag ]
Postings der letzten 30 Tage anzeigen

[Brooklin]

Antwort auf Beitrag Nr.: 27.680.360 von Aktienspekulant am 13.02.07 14:30:41

Langsam wird es unverschämt ...

[Marc999]

Antwort auf Beitrag Nr.: 27.680.360 von Aktienspekulant am 13.02.07 14:30:41

einfach ausgelöscht ...

[Greco1]

Ich dachte der Thread ist bis 15.30Uhr gesperrt?


13.04Uhr @all Guten Tag

da sich anscheinend einigen User mein Posting
nicht erschliesst
werde ich den Thread für eine Denkpause
bis 15.30 Uhr schliessen.

MfG
MaatMOD

[Brooklin]

Antwort auf Beitrag Nr.: 27.680.754 von Greco1 am 13.02.07 14:47:44

Der andere

[1bull007]

ACHTUNG !


15.30 Uhr alle GLI Freunde treffen sich im Hauptthread.

Dann geht es los.

Titel: Die unglaubliche GLIF Story

In der Hauptrolle: Stan
Nebenrolle Chi.Lin

Statisten: die GLIF Aktionäre

Drehort: Der Zauberberg

[Viva-los-Tioz]

guten tag meine lieben gliffreunde,

wünsche uns für heute und den nächsten tagen,wochen viel freude mit glif

viele liebe grüße
euer viva

[Greco1]

Antwort auf Beitrag Nr.: 27.681.213 von 1bull007 am 13.02.07 15:06:19

Drehort: Der Zauberberg

Das hat was von einem Heimatfilm

Ist aber egal, solange wir nicht in Transilvanien einen Horror-Film drehen müssen!

[Marc999]

ab 15.30 geht es dann munter weiter ...

länger sperren wäre aber unfair, schließlich kann man die Schläger bei den Fußballausschreitungen in Leipzig auch nicht länger als ein paar Stunden festsetzen ... die armen ... dank unseres fantastischen rechtsstaates ... armes deutschland

[Aktienspekulant]

leute es wurde heftigst gesperrt:

fuzerl
scsimodo
seppelbroker

meiner meinung nach durch total unbegründete dinge deweiteren um mundtot zu machen freie meinungsäußerungen sind anscheinend nicht mehr erwünscht aber basher dürfen hier alles posten ohne mit folgen rechnen zu müßen

es stellte sich die frage warum die von bashern erzeugten falschaussagen nicht entfernt werden und keine bestrafung für diese leute gibt-das warf den verdacht auf das mods die basher unterstützen-daraugfhin ewurden jetzt mindestens 3 leute aus wo gesperrt die den verdacht auch hegen

wie seht ihr die sache?

für mich sieht es nach schnellem mundtot machen aus

[ParadoxBrain]

Antwort auf Beitrag Nr.: 27.681.611 von Aktienspekulant am 13.02.07 15:22:25

ich frag mich nun auch, was denn hier abgeht. Vielleicht sollten mal die Administratoren bei einem mir vollkommen unbekannten und damit auch nicht genannten Moderator intervenieren und ihrerseits mal ein Zeichen setzen!!!!!!!!!!!!

[KrisuKrisu]

seppelbroker hat mich gebeten bekannt zu geben,
das er gespert wurde!!!!

[Brooklin]

Oh Mann das ist nicht normal

[Greco1]

Ist das der Beginn eines Aufstandes gegen die MODS?

Jede Revolution hat mal klein angefangen!

[1bull007]

Hat jemand RT Kurse aus den US.

Ich erhoffe News in den nächsten Tagen.

Auf zum Hauptthread

[Brooklin]

Thread geht noch nicht, nicht mal Wort gehalten wird

[ParadoxBrain]

Antwort auf Beitrag Nr.: 27.681.790 von Greco1 am 13.02.07 15:28:54

Ist nur ein Mod, der glaubt er sei König Wallstreet

@mir vollkommen unbekannten und damit unbenannten Mod:
Beruhigen Sie sich, holen Sie sich einen Kaffee, sehen Sie sich einen Film an, kommen danach wieder zurück an Ihren PC und schauen Sich sich alles nochmal an. Vielleicht kommen Sie dann zu anderen Schlüssen.

[Haucher]

hi zusammen ein gewisser her mod hat wohl die uhrzeit vergessen!!!

[MaatMod]

Antwort auf Beitrag Nr.: 27.681.965 von Brooklin am 13.02.07 15:33:35

Hallo

um 15.29 Uhr habe ich den Haupthread entsperrt.

Auf Grund der Grösse des Threads dauert
es etwas bis die Entsperrung wirksam wird.

Deine Kritik ist somit hinfällig

MfG
MaatMOD

[Brooklin]

Antwort auf Beitrag Nr.: 27.682.050 von MaatMod am 13.02.07 15:35:51

Das hättest Du ja miteinbeziehen können und bereits voher entsperren können

[Greco1]

Antwort auf Beitrag Nr.: 27.681.923 von 1bull007 am 13.02.07 15:32:41

RT 0,08 USD

[Brooklin]

Antwort auf Beitrag Nr.: 27.682.144 von Greco1 am 13.02.07 15:38:41

Haupthread geht wieder

[zapad]

was ist mit dem Thread?

gibt es da einen interessenskonflikt?